<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Intraoperative transfusion and administration of clotting factors
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Intraoperative transfusion and administration of clotting factors
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Intraoperative transfusion and administration of clotting factors
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Thomas J Graetz, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gregory Nuttall, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael F O'Connor, MD, FCCM
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven Kleinman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nancy A Nussmeier, MD, FAHA
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennifer S Tirnauer, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 20, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H508114005">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This topic will review general principles guiding intraoperative decisions to transfuse blood components, and the indications, risks, benefits, and alternatives for administration of specific components.
        </p>
        <p>
         Strategies employed to avoid or minimize perioperative transfusion are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/94347.html" rel="external">
          "Perioperative blood management: Strategies to minimize transfusions"
         </a>
         .)
        </p>
        <p>
         The following intraoperative circumstances are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cardiac surgery after cardiopulmonary bypass – (See
         <a class="medical medical_review" href="/z/d/html/122792.html" rel="external">
          "Achieving hemostasis after cardiac surgery with cardiopulmonary bypass", section on 'Transfusion of red blood cells'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/122792.html" rel="external">
          "Achieving hemostasis after cardiac surgery with cardiopulmonary bypass", section on 'Transfusion of other blood components'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perioperative massive transfusion – (See
         <a class="medical medical_review" href="/z/d/html/7931.html" rel="external">
          "Massive blood transfusion"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Indications for and general risks associated with transfusion of specific blood components in any setting are addressed in separate topics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Red blood cells (adults) (see
         <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">
          "Indications and hemoglobin thresholds for RBC transfusion in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Red blood cells (children) (see
         <a class="medical medical_review" href="/z/d/html/5910.html" rel="external">
          "Red blood cell transfusion in infants and children: Indications"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Plasma (see
         <a class="medical medical_review" href="/z/d/html/7920.html" rel="external">
          "Clinical use of plasma components"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Platelets (see
         <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">
          "Platelet transfusion: Indications, ordering, and associated risks"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cryoprecipitate (see
         <a class="medical medical_review" href="/z/d/html/7943.html" rel="external">
          "Cryoprecipitate and fibrinogen concentrate"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4216519216">
         <span class="h1">
          PREPARATIONS FOR LARGE EXPECTED BLOOD LOSSES
         </span>
        </p>
        <p class="headingAnchor" id="H2462527616">
         <span class="h2">
          Elective surgery with risk for significant blood loss
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Estimate expected blood loss
         </strong>
         – For elective procedures associated with clinically significant bleeding, the patient's total blood volume and the overall amount and rate of expected blood loss are estimated in the preoperative period in consultation with the surgeon. (See
         <a class="local">
          'Estimating blood loss'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type and crossmatch
         </strong>
         – Pretransfusion testing (typing and crossmatching) for red blood cells (RBCs) is routinely performed in the preoperative period for selected procedures with known risk for significant blood loss (eg, open repair of abdominal aortic aneurysm, hepatic resection). For such cases, RBC units should be cross matched and readily available for the operating team before surgical incision. If large volume blood loss is possible, preoperative communication between the anesthesiologist and the transfusion service is necessary to ensure that additional RBC units and other blood components will be readily available during the surgical procedure, and that there are no risk factors affecting access to additional cross-matched units (eg, rare blood type or known RBC alloantibodies). (See
         <a class="medical medical_review" href="/z/d/html/7953.html" rel="external">
          "Pretransfusion testing for red blood cell transfusion"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to procedure-specific factors, the likelihood of transfusion is also influenced by preoperative laboratory evidence of coagulopathy and/or presence of anemia [
         <a href="#rid1">
          1,2
         </a>
         ]. In a large retrospective study of 672,075 patients who had a coagulation profile obtained before common elective noncardiac and cardiac surgical procedures, abnormal findings in the preoperative international normalized ratio (INR) or platelet count were associated with risk of bleeding resulting in transfusion during both the intraoperative and postoperative periods [
         <a href="#rid3">
          3
         </a>
         ]. Preoperative anemia should be addressed before any elective surgical procedure if possible (ie, the underlying cause determined and optimal treatment provided) [
         <a href="#rid4">
          4
         </a>
         ]. Details are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/94347.html" rel="external">
          "Perioperative blood management: Strategies to minimize transfusions", section on 'Treatment of anemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prepare for blood conservation techniques when appropriate
         </strong>
         – In many cases, management includes planning for use of intraoperative techniques such as acute normovolemic hemodilution (ANH) or blood salvage to avoid or minimize the need for allogeneic transfusions. Indications, candidate selection, and technical aspects of these surgical blood conservation techniques are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7936.html" rel="external">
          "Surgical blood conservation: Acute normovolemic hemodilution"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7937.html" rel="external">
          "Surgical blood conservation: Intraoperative blood salvage"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1748295570">
         <span class="h2">
          Emergency surgery with possibility of massive blood transfusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with hemorrhage who require emergency surgery and possibly massive transfusion, early communication with the institutional blood bank or transfusion medicine service is necessary for activation of a massive transfusion protocol to order appropriate amounts and types of blood components. Details are discussed in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/7931.html" rel="external">
          "Massive blood transfusion"
         </a>
         .)
        </p>
        <p>
         Typically, RBCs, plasma, and platelets are ordered and transfused in approximately equal (1:1:1) ratios as soon as these blood components are available (either before and/or during surgery). If RBC units have not been made available and blood is urgently needed, the transfusion service can provide "immediate release" blood without pretransfusion testing. The universal donor for immediate release RBCs is type O, RhD-negative. The universal donor for immediate release plasma is type AB, RhD-positive. (See
         <a class="medical medical_review" href="/z/d/html/7953.html" rel="external">
          "Pretransfusion testing for red blood cell transfusion", section on 'Emergency release blood for life-threatening anemia or bleeding'
         </a>
         .)
        </p>
        <p>
         Examples of surgical cases that may encounter early activation of a massive transfusion protocol include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trauma surgery
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/7931.html" rel="external">
          "Massive blood transfusion", section on 'Trauma'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113837.html" rel="external">
          "Initial management of moderate to severe hemorrhage in the adult trauma patient"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aortic rupture
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/16843.html" rel="external">
          "Surgical and endovascular repair of ruptured abdominal aortic aneurysm", section on 'Preparation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Obstetric hemorrhage
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/6712.html" rel="external">
          "Postpartum hemorrhage: Management approaches requiring laparotomy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3291147393">
         <span class="h1">
          TECHNICAL ASPECTS OF BLOOD TRANSFUSION
         </span>
        </p>
        <p class="headingAnchor" id="H3424598618">
         <span class="h2">
          Establishing intravenous access
         </span>
         <span class="headingEndMark">
          —
         </span>
         If significant blood loss is anticipated, adequate intravenous (IV) access is necessary for possible blood product transfusion(s). If rapid fluid and blood product administration is anticipated, large-bore catheters with short lumens should be employed for optimal flow, in addition to the use of rapid infusion systems that will allow administration of large volumes more quickly [
         <a href="#rid5">
          5,6
         </a>
         ]. If patient positioning for the planned surgical procedure will create challenges for obtaining additional access, all IV catheters should be inserted prior to final positioning, with confirmation of patency and flow after final patient positioning.
        </p>
        <p>
         Either peripheral or central routes of access may be selected:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Peripheral venous access
         </strong>
         – Large-bore (eg, 14 or 16 gauge) peripheral IV catheters (or a short 7 French rapid infusion catheter inserted using a modified Seldinger technique) may be selected [
         <a href="#rid7">
          7,8
         </a>
         ]. Peripheral catheters are typically placed in the upper extremities. Compared with a central venous catheter (CVC), peripheral catheters are generally associated with fewer complications. However, large-bore peripheral venous access is not feasible in some patients due to body habitus, vein fragility, or prior use of multiple peripheral veins. (See
         <a class="medical medical_review" href="/z/d/html/13824.html" rel="external">
          "Peripheral venous access in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central venous access
         </strong>
         – A single-lumen, large-bore central venous introducer sheath or other CVC with large lumen(s) provides reliable access for blood and fluid administration, as well as central venous access for infusion of vasoactive agents. Either a multilumen CVC or a large, single-lumen introducer sheath (typically, 8.5 French) may be used. Multilumen catheters have limited flow properties due to long length and smaller lumens, while an introducer sheath allows rapid flow through its single lumen (and may be used for later placement of a pulmonary artery catheter [PAC] if necessary) [
         <a href="#rid9">
          9,10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8194.html" rel="external">
          "Central venous access in adults: General principles"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3804639820">
         <span class="h2">
          Avoiding transfusion errors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Practices to ensure that the intended blood components are given to the intended recipient are critical for preventing serious transfusion reactions. Extra caution is required to ensure that individuals caring for the patient do not bypass manual system checks that are in place to avoid errors during urgent surgical cases. Safety improvements such as barcode scanners installed in operating rooms increase adherence to protocols and may decrease likelihood of transfusion errors [
         <a href="#rid11">
          11,12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7939.html" rel="external">
          "Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Pre-transfusion considerations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2729092101">
         <span class="h2">
          Use of filters
         </span>
         <span class="headingEndMark">
          —
         </span>
         All red blood cell (RBC) units, plasma, and platelets should be transfused through a standard 170 to 260 micron filter (contained as an integral part of a standard infusion set), which is designed to remove clots and aggregates.
        </p>
        <p>
         In the United States, most blood product units released for transfusion are leukoreduced at the time of collection. If pre-storage leukoreduction was not performed, an add-on filter for leukoreduction may be used, although these filters will likely restrict rapid flow of blood during emergency transfusion. (See
         <a class="medical medical_review" href="/z/d/html/7939.html" rel="external">
          "Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Pre-storage leukoreduction'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2405864533">
         <span class="h2">
          Thawing and warming components, use of blood warmers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Frozen blood components are thawed on demand. Refrigerated components such as RBCs should be kept cold until a decision has been made to transfuse each one.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          RBCs and plasma
         </strong>
         – When possible, cold and previously thawed blood components (RBC units and plasma) should be administered via a blood warmer to avoid causing systemic hypothermia with resultant coagulopathy and other adverse effects [
         <a href="#rid13">
          13-20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cryoprecipitate and platelets
         </strong>
         – Cryoprecipitate units are thawed to room temperature and should be administered within six hours of thawing; use of a blood warmer is unnecessary. Platelets are stored at room temperature and are typically infused via separate IV tubing that is not connected to a blood warmer. However, if the patient is hypothermic, use of a blood warmer to administer cryoprecipitate or platelets is not prohibited [
         <a href="#rid21">
          21,22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7939.html" rel="external">
          "Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Administering the transfusion'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1390689124">
         <span class="h2">
          Administration with compatible fluids
         </span>
         <span class="headingEndMark">
          —
         </span>
         Only compatible fluids are coadministered with RBCs through the IV tubing (see
         <a class="medical medical_review" href="/z/d/html/7939.html" rel="external">
          "Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Compatible fluids'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If dilution of packed RBCs is necessary (such as during rapid intraoperative transfusion), the blood banking community recommends 0.9 percent
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         (normal saline).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         , albumin, or plasma can be administered through the same tubing as RBCs. Modern rapid infusion devices have reservoirs into which practitioners can add RBCs together with plasma in their desired combination (typically one plasma unit for each RBC unit).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In practice, anesthesiologists often coadminister other isotonic crystalloid solutions that have sodium and other electrolyte composition similar to plasma (eg,
         <a class="drug drug_general" data-topicid="108196" href="/z/d/drug information/108196.html" rel="external">
          lactated Ringer
         </a>
         's solution, Plasmalyte, Normosol) without adverse events.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dextrose (5 percent in water) or hypotonic solutions (eg, 0.45 percent
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         ) should never be coadministered with RBCs, because RBCs will take up glucose and/or free water and lyse. Hypertonic solutions (eg, 3 percent saline) should also be avoided.
        </p>
        <p>
        </p>
        <p>
         Other blood components (eg, platelets, cryoprecipitate) should be administered alone via separate tubing, or in tubing containing 0.9 percent sodium chloride. Importantly, cryoprecipitate may clot in IV tubing if that tubing still contains active thrombin from previously transfused blood components such as platelets [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H355865634">
         <span class="h2">
          Returning unused components
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unused blood components must be returned to the blood bank for possible use in another patient or appropriate disposal.
        </p>
        <p>
         To avoid wastage, RBCs should be removed from refrigerated storage immediately before use and should never be left to warm up at room temperature for long periods. RBC units that were not transfused should be returned to the blood bank with notation regarding the duration they were out of refrigerated storage. This helps with record-keeping. The blood bank will not transfuse RBCs to another person if they were unrefrigerated for longer than 30 to 60 minutes [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7939.html" rel="external">
          "Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Storage/transport temperature'
         </a>
         .)
        </p>
        <p>
         Blood components that are not needed are never transfused to avoid wastage, because this exposes the patient to unnecessary risks.
        </p>
        <p class="headingAnchor" id="H80035629">
         <span class="h1">
          GENERAL PRINCIPLES FOR TRANSFUSION DECISIONS
         </span>
        </p>
        <p class="headingAnchor" id="H1676693803">
         <span class="h2">
          When to transfuse
         </span>
         <span class="headingEndMark">
          —
         </span>
         Transfusions are a potentially lifesaving temporizing measure in patients who are bleeding. However, controlling the source of bleeding is more important. (See
         <a class="local">
          'Use of a transfusion algorithm or protocol'
         </a>
         below.)
        </p>
        <p>
         Major factors influencing intraoperative decisions to transfuse red blood cells (RBCs) and other blood components include estimates of the amount of current and expected ongoing blood loss, evidence of intractable microvascular bleeding indicating coagulopathy, and clinical signs of anemia (eg, tachycardia, hypotension, dilute-appearing blood in the surgical field, pallor). The need to transfuse should be confirmed with diagnostic tests for anemia and coagulation function whenever possible.
        </p>
        <p>
         For individuals without rapid bleeding, further administration of RBCs is avoided if the hemoglobin concentration is &gt;7 to 8 g/dL in healthy patients (or &gt;9 g/dL in older patients with high risk or evidence of ischemia). Supporting evidence for using this restrictive transfusion threshold and possible exceptions are discussed separately and below. (See
         <a class="local">
          'Red blood cells'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">
          "Indications and hemoglobin thresholds for RBC transfusion in adults"
         </a>
         .)
        </p>
        <p>
         Further administration of other blood components is avoided if active microvascular and surgical bleeding have ceased. However, individuals with active ongoing bleeding may require additional coagulation testing to guide appropriate selection of additional blood components. When bleeding is too rapid to be monitored with measurements of hemoglobin concentration, the number of transfused units is individualized based on estimated ongoing blood loss.
        </p>
        <p class="headingAnchor" id="H1787388488">
         <span class="h2">
          Estimating blood loss
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no clear consensus regarding optimal methods for assessing blood loss. The following methods are used, but are subject to inaccuracies [
         <a href="#rid26">
          26-33
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subjective estimates of blood loss, typically based on periodic visual assessment of the surgical field and communication with the surgeon regarding excessive microvascular bleeding at surgical dissection or wound sites and perceived volume and persistence of blood loss.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Estimates based on standard quantitative methods including monitoring blood suction canister volumes, the number and degree of saturation of surgical sponges and drapes, as well as serial laboratory measurements.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Trends in hemoglobin concentration could be misleading if time for equilibration is not permitted. Estimates are based on a combination of factors including blood components transfused, clinical estimates of circulating volume, and changes in hemoglobin.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8881114">
         <span class="h2">
          Intraoperative diagnostic testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Estimates of blood loss may prompt testing for anemia and hemostatic function to determine if administration of RBCs or other blood components is indicated (plasma, platelets, cryoprecipitate). These decisions are based in part on results of these tests, but the specific intraoperative context is always considered. (See
         <a class="local">
          'Indications and risks for specific blood components'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1901629482">
         <span class="h3">
          Standard tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Standard laboratory tests include hemoglobin concentration. In intraoperative settings, results of these tests may be available within a few minutes depending on local laboratory resources.
        </p>
        <p>
         Standard coagulation tests (prothrombin time [PT], international normalized ratio [INR], and activated partial thromboplastin time [aPTT]), fibrinogen level, and platelet count are obtained if coagulopathy is suspected. The time required for processing and reporting standard coagulation tests, platelet count, and fibrinogen concentration is typically 45 to 90 minutes and may be longer. Thus, the utility of these standard tests for assessing cause(s) of bleeding and coagulopathy is limited in rapidly changing intraoperative situations.
        </p>
        <p class="headingAnchor" id="H1787927592">
         <span class="h3">
          Point-of-care tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         When available, rapid point-of-care (POC) tests can provide more timely information compared with standard tests, allowing more rapid decision-making regarding the need for targeted transfusion of blood components.
        </p>
        <p class="headingAnchor" id="H1863476595">
         <span class="h4">
          Hemoglobin measurements
         </span>
         <span class="headingEndMark">
          —
         </span>
         In many institutions, rapid estimates of hemoglobin is obtained using arterial blood gas machines located in or near the operating room. We also use an automated analyzer for POC complete blood counts.
        </p>
        <p>
         Although POC instruments to measure hemoglobin are available, these are not as accurate as standard laboratory measurements [
         <a href="#rid34">
          34-39
         </a>
         ]. Accuracy can be altered by sample source (hemoglobin measurements are highest in capillary &gt; venous &gt; arterial blood samples), use of a tourniquet which falsely lowers hemoglobin levels, and administration of intravenous fluids which may acutely hemodilute the blood sample and decrease the hemoglobin level [
         <a href="#rid38">
          38,39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H468257718">
         <span class="h4">
          Tests of coagulation function
         </span>
         <span class="headingEndMark">
          —
         </span>
         POC tests of coagulation function allow rapid assessment of coagulopathy and responses to blood product transfusion. We agree with professional society recommendations regarding use of viscoelastic testing (VET), if available (eg, thromboelastography [TEG] or an adaptation of TEG known as rotational thromboelastometry [ROTEM]), to test overall coagulation function during selected surgical procedures such as cardiac surgery or liver transplant [
         <a href="#rid40">
          40-50
         </a>
         ]. The role of viscoelastic POC methods continues to develop in other patient populations with significant bleeding, including obstetrics and orthopedic surgery [
         <a href="#rid51">
          51
         </a>
         ]. However, VETs are not available in every institution [
         <a href="#rid52">
          52
         </a>
         ]. Even in institutions that do use VETs, standard laboratory coagulation tests are also recommended to provide additional information [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         With VET, a tracing result provides information regarding clot initiation, kinetics of clot formation, clot strength, and fibrinolysis  (
         <a class="graphic graphic_figure graphicRef80241" href="/z/d/graphic/80241.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef100078" href="/z/d/graphic/100078.html" rel="external">
          figure 2
         </a>
         and
         <a class="graphic graphic_table graphicRef74954" href="/z/d/graphic/74954.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary fibrinolysis  (
         <a class="graphic graphic_figure graphicRef58281 graphicRef51767" href="/z/d/graphic/58281.html" rel="external">
          figure 3A-B
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Secondary hyperfibrinolysis  (
         <a class="graphic graphic_figure graphicRef58281 graphicRef70388" href="/z/d/graphic/58281.html" rel="external">
          figure 3A, 3C
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombocytopenia  (
         <a class="graphic graphic_figure graphicRef58281 graphicRef80926" href="/z/d/graphic/58281.html" rel="external">
          figure 3A, 3D
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clotting factor consumption  (
         <a class="graphic graphic_figure graphicRef58281 graphicRef60690" href="/z/d/graphic/58281.html" rel="external">
          figure 3A, 3E
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypercoagulability  (
         <a class="graphic graphic_figure graphicRef58281 graphicRef58977" href="/z/d/graphic/58281.html" rel="external">
          figure 3A, 3F
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         In general, randomized trials and observational studies in surgical patients have noted that use of VET (with or without a transfusion algorithm) reduces RBC and possibly FFP and platelet transfusions, compared with standard care based on standard laboratory coagulation tests and/or clinical judgment, although results are inconsistent, particularly in noncardiac surgical procedures [
         <a href="#rid45">
          45,50,53-89
         </a>
         ]. Evidence presented in meta-analyses has been limited by heterogeneity among studies since the TEG or ROTEM parameters used for a transfusion algorithm or protocol were institution-specific for each study, as well as high risk of bias, imprecision, and/or indirectness [
         <a href="#rid53">
          53-58,77,79,80
         </a>
         ].
        </p>
        <p>
         VET-based transfusion of blood components is also commonly used to manage the acute coagulopathy associated with trauma. Although VETs can be performed rapidly, patients requiring resuscitation using a rapid transfuser device are less likely to benefit from such testing compared with those undergoing transfusion of fewer units at a slower rate. Details are discussed in other topics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="local">
          'Use of a transfusion algorithm or protocol'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">
          "Clinical use of coagulation tests", section on 'Point-of-care testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15147.html" rel="external">
          "Etiology and diagnosis of coagulopathy in trauma patients", section on 'Viscoelastic hemostatic assays'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/117817.html" rel="external">
          "Ongoing assessment, monitoring, and resuscitation of the severely injured patient", section on 'VHA-based dosing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Also, if available, POC aggregometry may be performed to test platelet function when platelet dysfunction is suspected. Detecting a residual effect of P2Y12 inhibitors may be helpful in the setting of mild to moderate bleeding. However, testing for platelet dysfunction may not be useful in an actively bleeding patient if results are not immediately available, and the accuracy of most tests depends on a relatively normal platelet count. Also, these tests are not accurate after cardiopulmonary bypass due to dilutional changes and platelet activation [
         <a href="#rid90">
          90
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15147.html" rel="external">
          "Etiology and diagnosis of coagulopathy in trauma patients", section on 'Platelet dysfunction'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">
          "Clinical use of coagulation tests"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4433.html" rel="external">
          "Platelet function testing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2316135045">
         <span class="h2">
          Use of a transfusion algorithm or protocol
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar to recommendations in the practice guidelines of several professional societies, we use a goal-directed protocol or algorithm to guide transfusion decisions based on measurement of hemoglobin and assessment of specific abnormalities of coagulation, either obtained from standard laboratory tests or POC viscoelastic tests VET, such as TEG  (
         <a class="graphic graphic_table graphicRef74954" href="/z/d/graphic/74954.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef56058" href="/z/d/graphic/56058.html" rel="external">
          table 2
         </a>
         ) or ROTEM [
         <a href="#rid40">
          40-49,89
         </a>
         ].
        </p>
        <p>
         Overall, use of an algorithm reduces unnecessary transfusions of RBCs, plasma, platelets, and cryoprecipitate while allowing optimal treatment of coagulopathy during major surgical procedures. However, no trials have prospectively compared different algorithms. (See
         <a class="local">
          'Standard tests'
         </a>
         above and
         <a class="local">
          'Point-of-care tests'
         </a>
         above.)
        </p>
        <p>
         For patients with severe and ongoing or massive hemorrhage, transfusion decisions are not based exclusively on the most recent hemoglobin value and tests of hemostasis. In such patients, more aggressive transfusion may be necessary to compensate for ongoing blood loss, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7931.html" rel="external">
          "Massive blood transfusion", section on 'Approach to volume and blood replacement'
         </a>
         .)
        </p>
        <p>
         It is imperative to continue efforts to control the source of bleeding even as a patient is being massively transfused, as it is source control, not transfusion, that is the definitive treatment. Transfusion is only a temporizing measure until bleeding can be stopped. The ultimate manifestation of this concept is the "Stop the Bleed" campaign, in which bystanders are taught to apply a tourniquet to a limb that has sustained a life-threatening arterial injury [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1946109886">
         <span class="h1">
          INDICATIONS AND RISKS FOR SPECIFIC BLOOD COMPONENTS
         </span>
        </p>
        <p class="headingAnchor" id="H2495218495">
         <span class="h2">
          Red blood cells
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of a restrictive transfusion strategy
         </strong>
         –
         <strong>
         </strong>
         We transfuse autologous, salvaged, or allogeneic red blood cell (RBC) units when the hemoglobin is below a specific threshold for the clinical situation. Typically, this involves hemoglobin &lt;7 to 8 g/dL in most cardiac and noncardiac surgical patients without significant ongoing bleeding. These threshold values are similar to the guidelines of several professional societies for use of a restrictive transfusion strategy [
         <a href="#rid40">
          40-42,44,46-49,92,93
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">
          "Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Overview of our approach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Trials in surgical patients (including older adults with comorbidities) have compared restrictive transfusion strategies (typically defined as Hgb &lt;7 or &lt;8 g/dL, depending on the study) versus more liberal transfusion strategies (typically defined as Hgb &lt;9 or &lt;10 g/dL). Most have noted decreases in the number of RBC units transfused in patients managed with a restrictive strategy, without higher incidences of mortality, myocardial infarction, stroke, kidney failure, or infection with either strategy [
         <a href="#rid41">
          41,44,46-49,94-110
         </a>
         ]. Although the majority of studies show no benefit from liberal transfusions, restrictive strategy has been associated with increased risk of mortality in selected studies [
         <a href="#rid111">
          111,112
         </a>
         ]. Important limitations of trials comparing restrictive versus liberal transfusion strategies include variability in post-transfusion hemoglobin targets, difficulties in precisely maintaining a selected target, differences in endpoints (eg, percentage of patients transfused versus number of units transfused per patient), and differences in the time periods studied (eg, intraoperative, postoperative, or both periods) [
         <a href="#rid113">
          113
         </a>
         ]. These trials are summarized in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">
          "Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Thresholds for specific patient populations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The decisions to transfuse RBC units are carefully considered and individualized. For example, if a patient is known to tolerate a hemoglobin concentration &lt;7 g/dL, then there may not be a need for transfusion. Conversely, we typically use a hemoglobin threshold of &lt;9 g/dL in patients with known acute coronary syndrome or signs of myocardial or other organ ischemia [
         <a href="#rid94">
          94,95,111,114-120
         </a>
         ]. Myocardial ischemia may be diagnosed by changes noted on the electrocardiogram (ECG), pulmonary artery catheter (PAC), or with transesophageal echocardiography (TEE), while poor perfusion and ischemia of other organs may manifest as increased lactate levels or decreased mixed venous oxygen saturation, or urine output. Also, in cases with rapid blood loss or significant ongoing bleeding, immediate transfusion may be necessary before quantitative laboratory assessment of hemoglobin can be obtained, based on the rate of bleeding, expected volume of ongoing bleeding, and the preoperative red cell mass. However, there is general consensus that transfusion of packed RBC units is recommended if Hgb &lt;6 g/dL, and that transfusion is rarely indicated if Hgb &gt;10 g/dL. (See
         <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">
          "Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Thresholds for specific patient populations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We reassess hemoglobin levels after transfusion to inform decisions regarding whether additional RBC units are needed. Accurate assessment of a post-transfusion hemoglobin level can be performed as early as 15 minutes following completion of RBC administration (in the absence of ongoing active bleeding) [
         <a href="#rid121">
          121,122
         </a>
         ]. However, when blood loss is rapid and significant, immediate life-saving transfusion may be necessary before quantitative laboratory assessment of hemoglobin can be obtained, based on the rate of bleeding and expected total volume of blood [
         <a href="#rid41">
          41,42
         </a>
         ]. Although noninvasive hemoglobin measurements are still obtained in such situations, these will not accurately reflect the degree of reduced red cell mass [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risks of transfusion
         </strong>
         –
         <strong>
         </strong>
         There are inherent risks associated with either perioperative anemia and with transfusion as a therapy [
         <a href="#rid123">
          123
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Adverse events can occur in individuals receiving transfusions. Some adverse events are likely related to severity of comorbidities rather than direct complications of transfusion:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Infection and immunomodulation [
         <a href="#rid124">
          124-127
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cardiovascular complications [
         <a href="#rid123">
          123,128
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mortality [
         <a href="#rid111">
          111,112,122-124,127,129
         </a>
         ]
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Acute kidney injury [
         <a href="#rid106">
          106,107,123,130
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         General risks associated with transfusion of RBCs are noted below. (See
         <a class="local">
          'Risks of blood transfusion'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Massive transfusion can be associated with additional risks including metabolic complications [
         <a href="#rid131">
          131,132
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7931.html" rel="external">
          "Massive blood transfusion", section on 'Complications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1585.html" rel="external">
          "Early noncardiac complications of coronary artery bypass graft surgery", section on 'Blood transfusion'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risks of anemia
         </strong>
         –
         <strong>
         </strong>
         Anemia has been associated with higher mortality in surgical patients [
         <a href="#rid133">
          133-135
         </a>
         ]. In one study of patients who declined perioperative transfusion, mortality was 21 percent in those with a hemoglobin nadir of 6.1 to 7 g/dL, but increased to 41 percent in those with a lower hemoglobin nadir of 5.1 to 6 g/dL [
         <a href="#rid133">
          133
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">
          "Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Rationale for transfusion'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1076013941">
         <span class="h2">
          Platelets
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – Similar to recommendations in the practice guidelines of several professional societies, we transfuse platelets to maintain adequate platelet count in surgical patients, typically &gt;50,000/microL or &gt;100,000/microL when central nervous system bleeding is present or likely [
         <a href="#rid40">
          40-49,89,136
         </a>
         ]. Platelet transfusions are also a component of massive transfusion protocols. Most recommendations are based on expert consensus; evidence is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">
          "Platelet transfusion: Indications, ordering, and associated risks", section on 'Indications for platelet transfusion'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Abnormalities of platelet function affect clotting even if platelet count is adequate. Thus, if ongoing bleeding is suspected to be due to qualitative platelet defects, platelet transfusion may be used [
         <a href="#rid136">
          136
         </a>
         ]. Examples include emergency surgery in patients with qualitative platelet defects caused by chronic use of antiplatelet agents that inhibit cyclooxygenase, glycoprotein IIb/IIIa, and/or adenosine diphosphate (ADP), or uremic platelet dysfunction when there is insufficient time for dialysis. (See
         <a class="medical medical_review" href="/z/d/html/1947.html" rel="external">
          "Uremic platelet dysfunction", section on 'Invasive procedures'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Platelet dysfunction due to
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">
          dipyridamole
         </a>
         , P2Y
         <sub>
          12
         </sub>
         receptor antagonists, or reversible GP IIbIIIa antagonists (eg,
         <a class="drug drug_general" data-topicid="8918" href="/z/d/drug information/8918.html" rel="external">
          eptifibatide
         </a>
         ) may not be detected by point-of-care (POC) viscoelastic testing (VET) such as thromboelastography (TEG) or rotational thromboelastometry (ROTEM) [
         <a href="#rid50">
          50,137
         </a>
         ]. (See
         <a class="local">
          'Tests of coagulation function'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Further information regarding the utility of POC tests of coagulation for diagnosis of platelet-dependent bleeding is available in separate topics:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">
          "Platelet transfusion: Indications, ordering, and associated risks", section on 'Specific clinical scenarios'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">
          "Clinical use of coagulation tests", section on 'Point-of-care testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15147.html" rel="external">
          "Etiology and diagnosis of coagulopathy in trauma patients", section on 'Viscoelastic hemostatic assays'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/117817.html" rel="external">
          "Ongoing assessment, monitoring, and resuscitation of the severely injured patient", section on 'VHA-based dosing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We typically avoid prophylactic intraoperative platelet transfusions in patients who are not bleeding, especially if the platelet count is &gt;50,000/microL [
         <a href="#rid138">
          138
         </a>
         ]. Exceptions may be made if consequences of even minor bleeding would be severe (eg, ophthalmic procedures or neurosurgery), or if a surgical procedure is likely to cause significant bleeding. (See
         <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">
          "Platelet transfusion: Indications, ordering, and associated risks", section on 'Actively bleeding patient'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preparations
         </strong>
         – Platelets can be obtained by apheresis from a single donor or as pooled units of whole blood derived platelets (typically derived from whole blood donations from four to six different donors)  (
         <a class="graphic graphic_table graphicRef53854" href="/z/d/graphic/53854.html" rel="external">
          table 3
         </a>
         ). One apheresis unit is equivalent to four to six pooled platelet units. Although exact platelet quantities vary, each platelet dose (one apheresis unit or a pool of whole blood derived platelets) contains approximately 3 to 4 x 10
         <sup>
          11
         </sup>
         platelets suspended in 200 to 300 mL of plasma and will increase the platelet count by approximately 30,000/microL to 50,000/microL in a non-bleeding adult  (
         <a class="graphic graphic_table graphicRef53854" href="/z/d/graphic/53854.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">
          "Platelet transfusion: Indications, ordering, and associated risks", section on 'Whole blood derived (WBD) versus apheresis platelets'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risks
         </strong>
         – General risks of platelet transfusion, including alloimmunization, are the same as other blood components, as noted below [
         <a href="#rid139">
          139
         </a>
         ]. (See
         <a class="local">
          'Risks of blood transfusion'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Historically, the risk of bacterial infection is higher with platelets compared with other blood components due to storage at room temperature; this increased risk has been substantially mitigated by the addition of risk reduction methods (eg, bacterial culture and pathogen inactivation). Rarely, post-transfusion purpura may occur. (See
         <a class="medical medical_review" href="/z/d/html/3805.html" rel="external">
          "Transfusion-transmitted bacterial infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4129789782">
         <span class="h2">
          Plasma
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications
         </strong>
         – The main indication for plasma, including Fresh Frozen Plasma (FFP) or plasma frozen within 24 hours of collection (PF24), is reversal of warfarin in preparation for urgent surgery when a prothrombin complex concentrate (PCC) is not available  (
         <a class="graphic graphic_table graphicRef79151" href="/z/d/graphic/79151.html" rel="external">
          table 4
         </a>
         ). The initial dose depends on body weight and internation normalized ratio (INR) and is adjusted using laboratory testing. (See
         <a class="medical medical_review" href="/z/d/html/1312.html" rel="external">
          "Perioperative management of patients receiving anticoagulants", section on 'Urgent/emergency invasive procedure'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">
          "Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Urgent surgery/procedure'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Similar to recommendations in the practice guidelines of several professional societies, other intraoperative uses of plasma include  (
         <a class="graphic graphic_table graphicRef53854" href="/z/d/graphic/53854.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid40">
          40-49
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         As a component of massive transfusion protocols. (See
         <a class="medical medical_review" href="/z/d/html/7931.html" rel="external">
          "Massive blood transfusion", section on 'Approach to volume and blood replacement'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients with ongoing clinically significant bleeding, particularly if intracranial hemorrhage is present, if there are suspected or documented severe abnormalities of clotting (eg, INR &gt;2.0 or abnormalities of viscoelastic testing due to vitamin K deficiency)  (
         <a class="graphic graphic_figure graphicRef58281 graphicRef60690" href="/z/d/graphic/58281.html" rel="external">
          figure 3A, 3E
         </a>
         ) [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="local">
          'Tests of coagulation function'
         </a>
         above and
         <a class="local">
          'Standard tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         However, plasma is not administered to stable nonbleeding patients solely to "correct" an elevated INR (INR up to 2) [
         <a href="#rid140">
          140
         </a>
         ]. The rationale is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7920.html" rel="external">
          "Clinical use of plasma components", section on 'Settings in which plasma is not appropriate'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other rare indications that may be relevant in the perioperative period are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7920.html" rel="external">
          "Clinical use of plasma components", section on 'Overview of indications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risks
         </strong>
         – Risks of FFP transfusion are noted below. (See
         <a class="local">
          'Risks of blood transfusion'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1345675862">
         <span class="h2">
          Cryoprecipitate or fibrinogen concentrate
         </span>
         <span class="headingEndMark">
          —
         </span>
         As stated in the practice guidelines of several professional societies [
         <a href="#rid40">
          40-49
         </a>
         ], cryoprecipitate or
         <a class="drug drug_general" data-topicid="9082" href="/z/d/drug information/9082.html" rel="external">
          fibrinogen concentrate
         </a>
         is administered to patients with clinically significant bleeding when the fibrinogen concentration is &lt;150 mg/dL or when hypofibrinogenemia is suspected and fibrinogen cannot be measured in a timely fashion  (
         <a class="graphic graphic_table graphicRef53854" href="/z/d/graphic/53854.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid88">
          88,141-144
         </a>
         ]. Abnormally low concentrations of fibrinogen can result in impaired clot formation and increased bleeding.
        </p>
        <p>
         Clinical use of cryoprecipitate has become obsolete in some parts of Europe due to the availability of fibrinogen concentrates [
         <a href="#rid145">
          145-147
         </a>
         ]. In the United States and the United Kingdom, cryoprecipitate is still commonly used because of its wider availability and lower cost compared with
         <a class="drug drug_general" data-topicid="9082" href="/z/d/drug information/9082.html" rel="external">
          fibrinogen concentrate
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/1321.html" rel="external">
          "Disorders of fibrinogen", section on 'Fibrinogen concentrate: Dosing and monitoring'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications and uses
         </strong>
         –
         <a class="drug drug_general" data-topicid="9082" href="/z/d/drug information/9082.html" rel="external">
          Fibrinogen concentrate
         </a>
         or cryoprecipitate has been used to treat life-threatening intraoperative bleeding due to:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypofibrinogenemia, with fibrinogen concentration &lt;150 mg/dL [
         <a href="#rid44">
          44,148
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/122792.html" rel="external">
          "Achieving hemostasis after cardiac surgery with cardiopulmonary bypass", section on 'Cryoprecipitate versus fibrinogen concentrate'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1321.html" rel="external">
          "Disorders of fibrinogen", section on 'Treatment/prevention of bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Disseminated intravascular coagulation (DIC) with active bleeding and low fibrinogen. (See
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Prevention/treatment of bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Uremic bleeding. (See
         <a class="medical medical_review" href="/z/d/html/7943.html" rel="external">
          "Cryoprecipitate and fibrinogen concentrate", section on 'Uremic bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hepatic insufficiency with active bleeding and low fibrinogen. (See
         <a class="medical medical_review" href="/z/d/html/13932.html" rel="external">
          "Hemostatic abnormalities in patients with liver disease", section on 'Bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Postpartum hemorrhage. (See
         <a class="medical medical_review" href="/z/d/html/6710.html" rel="external">
          "Overview of postpartum hemorrhage", section on 'Recognize alarm findings and intervene early'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/130462.html" rel="external">
          "Disseminated intravascular coagulation (DIC) during pregnancy: Management and prognosis", section on 'Blood products'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Treatment of excessive bleeding and coagulopathy during massive blood loss if hypofibrinogenemia is strongly suspected and testing is not available or lags behind [
         <a href="#rid44">
          44,143,145-147,149-160
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7943.html" rel="external">
          "Cryoprecipitate and fibrinogen concentrate", section on 'Use in specific settings'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1321.html" rel="external">
          "Disorders of fibrinogen", section on 'Acute bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H192745402">
         <span class="h3">
          Cryoprecipitate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cryoprecipitate is preferred over plasma to treat documented hypofibrinogenemia when there are no other clotting factor deficiencies and
         <a class="drug drug_general" data-topicid="9082" href="/z/d/drug information/9082.html" rel="external">
          fibrinogen concentrate
         </a>
         is not available. (See
         <a class="medical medical_review" href="/z/d/html/7943.html" rel="external">
          "Cryoprecipitate and fibrinogen concentrate"
         </a>
         .)
        </p>
        <p>
         Differences between cryoprecipitate and
         <a class="drug drug_general" data-topicid="9082" href="/z/d/drug information/9082.html" rel="external">
          fibrinogen concentrate
         </a>
         are summarized in the table  (
         <a class="graphic graphic_table graphicRef102695" href="/z/d/graphic/102695.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – The typical cryoprecipitate dose, as received from the blood bank, is a pooled product that has been prepared by combining individual cryoprecipitate units derived from 5 to 10 blood donors in a volume of 50 to 200 mL  (
         <a class="graphic graphic_table graphicRef53854" href="/z/d/graphic/53854.html" rel="external">
          table 3
         </a>
         ). This typical dose contains all of the fibrinogen present in one unit of whole blood (approximately 200 to 400 mg), as well as most of the factor VIII, factor XIII, von Willebrand factor (VWF), and fibronectin derived from one unit of FFP in a small volume of 10 to 20 mL (rather than 250 to 300)  (
         <a class="graphic graphic_table graphicRef53854" href="/z/d/graphic/53854.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef102695" href="/z/d/graphic/102695.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Dosing with a 5-unit bag of cryoprecipitate will increase fibrinogen levels by approximately 35 to 50 mg/dL in a 70 kg adult (each unit of cryoprecipitate raises the fibrinogen concentration by approximately 7 to 10 mg/dL), although this increase may be less if the patient is actively hemorrhaging [
         <a href="#rid161">
          161
         </a>
         ]. Similar to
         <a class="drug drug_general" data-topicid="9082" href="/z/d/drug information/9082.html" rel="external">
          fibrinogen concentrate
         </a>
         , the plasma fibrinogen level is monitored after administration to determine if repeat doses are necessary to maintain fibrinogen &gt;150 mg/dL. Higher levels are used in postpartum hemorrhage. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Correct clotting factor deficiencies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risks
         </strong>
         – Risks of cryoprecipitate transfusion are similar to those for FFP (see
         <a class="local">
          'Risks of blood transfusion'
         </a>
         below). However, hemolytic transfusion reactions and transfusion-associated circulatory overload (TACO) are less likely than with plasma since the total transfused volume will be substantially less. Also, due to the low volume of plasma in each unit, cryoprecipitate does not need to be ABO matched in adults. However, risk of infection per dose may be higher since the product is pooled from multiple donors. Safety considerations are discussed is a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/7943.html" rel="external">
          "Cryoprecipitate and fibrinogen concentrate", section on 'Cryoprecipitate adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H136391823">
         <span class="h3">
          Fibrinogen concentrate
         </span>
         <span class="headingEndMark">
          —
         </span>
         If available, we prefer a
         <a class="drug drug_general" data-topicid="9082" href="/z/d/drug information/9082.html" rel="external">
          fibrinogen concentrate
         </a>
         , rather than cryoprecipitate or plasma, to treat hypofibrinogenemia. In continental Europe and Canada, fibrinogen concentrate rather than cryoprecipitate is typically selected to treat hypofibrinogenemia (congenital or acquired), in part because cryoprecipitate is not typically available in these regions [
         <a href="#rid145">
          145-147
         </a>
         ]. Also, fibrinogen concentrate has less risk of infection transmission and immunological complications compared with cryoprecipitate or other blood components [
         <a href="#rid144">
          144,145,162
         </a>
         ]. However, fibrinogen concentrate has higher up-front costs than cryoprecipitate [
         <a href="#rid144">
          144,145
         </a>
         ].
        </p>
        <p>
         Proponents of
         <a class="drug drug_general" data-topicid="9082" href="/z/d/drug information/9082.html" rel="external">
          fibrinogen concentrate
         </a>
         argue that the natural baseline concentration of fibrinogen is relatively low, and there are no fibrinogen stores to be mobilized. Therefore, fibrinogen is the first coagulation protein to become critically low during intraoperative bleeding [
         <a href="#rid149">
          149
         </a>
         ]. A 2020 meta-analysis included 13 trials with 900 patients who had author-defined low fibrinogen level or clinically significant blood loss during any type of surgery [
         <a href="#rid163">
          163
         </a>
         ]. In this meta-analysis, blood loss was reduced in the first 12 postoperative hours in patients who received fibrinogen concentrate compared with those who received placebo, but the mean difference was only -135 mL (95% CI -183 to -87 mL), and results were inconsistent for other clinically important outcomes such as survival.
        </p>
        <p>
         However, guidelines do not suggest aiming for supranormal fibrinogen levels, and they do not recommend prophylactic administration of
         <a class="drug drug_general" data-topicid="9082" href="/z/d/drug information/9082.html" rel="external">
          fibrinogen concentrate
         </a>
         in individuals with normal fibrinogen levels [
         <a href="#rid145">
          145,146,164,165
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – The dose of
         <a class="drug drug_general" data-topicid="9082" href="/z/d/drug information/9082.html" rel="external">
          fibrinogen concentrate
         </a>
         is calculated according to the target fibrinogen concentration. (See
         <a class="medical medical_review" href="/z/d/html/1321.html" rel="external">
          "Disorders of fibrinogen", section on 'Fibrinogen concentrate: Dosing and monitoring'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Dosing is typically monitored with viscoelastic testing (VET) and monitoring of plasma fibrinogen level [
         <a href="#rid155">
          155,156
         </a>
         ]. However, use of VET to determine when and how to supplement fibrinogen in patients with intraoperative bleeding has been particularly challenging [
         <a href="#rid166">
          166
         </a>
         ]. (See
         <a class="local">
          'Point-of-care tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risks
         </strong>
         – Thromboembolic complications can occur, particularly in pregnant patients. Overcorrection of fibrinogen deficiency should be avoided to minimize this risk. While caution is warranted, most studies have not reported increased risk of thrombotic events [
         <a href="#rid153">
          153,157
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4215751200">
         <span class="h2">
          Risks of blood transfusion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Potential complications of blood component transfusion (including RBCs, plasma, platelets and cryoprecipitate) consist of hemolytic transfusion reactions, transfusion-related acute lung injury (TRALI) [
         <a href="#rid167">
          167
         </a>
         ], transfusion-related circulatory overload (TACO), transfusion-transmissible infections (bacterial, viral, or parasitic  (
         <a class="graphic graphic_table graphicRef69661" href="/z/d/graphic/69661.html" rel="external">
          table 6
         </a>
         )), transfusion-associated graft-versus-host disease (TA-GVHD), and transfusion-related immunomodulation that may lead to postoperative infection and other potential morbidities [
         <a href="#rid124">
          124
         </a>
         ]. Alloimmunization leading to reduced availability of compatible blood components can also occur. Notably, the incidence of TRALI and TACO may be higher in perioperative patients compared with nonsurgical patients [
         <a href="#rid167">
          167
         </a>
         ].
        </p>
        <p>
         These complications are discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">
          "Indications and hemoglobin thresholds for RBC transfusion in adults", section on 'Risks and complications of transfusion'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7918.html" rel="external">
          "Platelet transfusion: Indications, ordering, and associated risks", section on 'Complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7920.html" rel="external">
          "Clinical use of plasma components", section on 'Risks'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7943.html" rel="external">
          "Cryoprecipitate and fibrinogen concentrate", section on 'Cryoprecipitate adverse effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Massive transfusion may result in additional complications (eg, citrate toxicity with hypocalcemia, hyperkalemia, acidosis, hypothermia), which are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7931.html" rel="external">
          "Massive blood transfusion"
         </a>
         .)
        </p>
        <p>
         The approach to a patient with an acute transfusion reaction is discussed separately [
         <a href="#rid168">
          168,169
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/95132.html" rel="external">
          "Approach to the patient with a suspected acute transfusion reaction"
         </a>
         .)
        </p>
        <p>
         Evaluation of specific complications is discussed in separate topics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7947.html" rel="external">
          "Immunologic transfusion reactions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7926.html" rel="external">
          "Transfusion-related acute lung injury (TRALI)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7919.html" rel="external">
          "Transfusion-associated circulatory overload (TACO)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3805.html" rel="external">
          "Transfusion-transmitted bacterial infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7946.html" rel="external">
          "Blood donor screening: Laboratory testing", section on 'Viruses'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7928.html" rel="external">
          "Transfusion-associated graft-versus-host disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1975481416">
         <span class="h1">
          USE OF CLOTTING FACTORS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clotting factors have been administered to selected patients with persistent or severe intraoperative (or preoperative or postoperative) bleeding due to various causes of impaired coagulation. Ideally, any clotting factor administered should treat the specific deficiency. For example,
         <a class="drug drug_general" data-topicid="9082" href="/z/d/drug information/9082.html" rel="external">
          fibrinogen concentrate
         </a>
         may be administered to treat an isolated fibrinogen deficiency with fibrinogen concentration &lt;150 mg/dL in a patient with clinically significant bleeding, as noted above. (See
         <a class="local">
          'Fibrinogen concentrate'
         </a>
         above.).
        </p>
        <p>
         Intraoperative use of other clotting factors such as prothrombin complex concentrate (PCC; activated or unactivated) or factor VIII inhibitor bypassing agent (FIEBA), recombinant activated factor VII (rFVIIa) is discussed below. (See
         <a class="local">
          'Prothrombin complex concentrates (PCCs)'
         </a>
         below and
         <a class="local">
          'Recombinant activated factor VII (rFVIIa)'
         </a>
         below.)
        </p>
        <p>
         Intraoperative uses of hemostatic agents such as antifibrinolytics or
         <a class="drug drug_general" data-topicid="9330" href="/z/d/drug information/9330.html" rel="external">
          desmopressin
         </a>
         (DDAVP) are discussed in a separate topic. (See
         <a class="medical medical_review" href="/z/d/html/94347.html" rel="external">
          "Perioperative blood management: Strategies to minimize transfusions", section on 'Systemic hemostatic agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2405643102">
         <span class="h2">
          Prothrombin complex concentrates (PCCs)
         </span>
        </p>
        <p class="headingAnchor" id="H235749888">
         <span class="h3">
          Unactivated PCC
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications and uses
         </strong>
         — The two indications approved by the US Food and Drug Administration (FDA) for PCC is reversal of
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         for emergency invasive procedures or active bleeding on warfarin. While the prothrombin time and international normalized ratio (PT/INR) may "correct" the patient may still have ongoing abnormalities of coagulation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Advantages of using a PCC rather than plasma include rapid administration and small volume. For initial and sustained effect and for both plasma and PCC, concomitant administration of
         <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">
          vitamin K
         </a>
         is required. Compared with plasma, PCC carry less risk of volume overload and avoid transfusion reactions [
         <a href="#rid44">
          44,149,150,170-181
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">
          "Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Urgent surgery/procedure'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7925.html" rel="external">
          "Plasma derivatives and recombinant DNA-produced coagulation factors", section on 'PCCs'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Treatment of
         </strong>
         <strong>
          vitamin K
         </strong>
         <strong>
          antagonist anticoagulation
         </strong>
         – A four-factor PCC should be used; this contains factors II, VII, IX and X, heparin, antithrombin, protein C and S, and albumin.  (
         <a class="graphic graphic_table graphicRef94210" href="/z/d/graphic/94210.html" rel="external">
          table 7
         </a>
         ). PCCs are typically used to treat intraoperative bleeding associated with warfarin or another vitamin K antagonist, in combination with
         <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">
          vitamin K
         </a>
         [
         <a href="#rid170">
          170
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">
          "Management of warfarin-associated bleeding or supratherapeutic INR", section on 'PCC products'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1325.html" rel="external">
          "Reversal of anticoagulation in intracranial hemorrhage", section on 'Warfarin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Reversal of factor Xa inhibitors
         </strong>
         – A four-factor PCC can be used to treat life-threatening bleeding in a patient actively anticoagulated with a factor Xa inhibitor (
         <a class="drug drug_general" data-topicid="85642" href="/z/d/drug information/85642.html" rel="external">
          apixaban
         </a>
         ,
         <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">
          rivaroxaban
         </a>
         ,
         <a class="drug drug_general" data-topicid="99275" href="/z/d/drug information/99275.html" rel="external">
          edoxaban
         </a>
         ). Assessment of active anticoagulation and discussion of PCC versus andexanet alpha is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">
          "Management of bleeding in patients receiving direct oral anticoagulants", section on 'Factor Xa inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Treatment of intractable bleeding in selected surgical procedures
         </strong>
         – A PCC product may be reasonable in selected surgical patients with intractable coagulopathy and diffuse bleeding (eg, cardiac surgery with cardiopulmonary bypass [CPB], liver transplantation, trauma surgery), particularly if intolerance of high FFP transfusion volume is a factor. These uses of PCC and
         <a class="drug drug_general" data-topicid="9082" href="/z/d/drug information/9082.html" rel="external">
          fibrinogen concentrate
         </a>
         are off label in the United States.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Cardiac surgery
         </strong>
         – Off-label intraoperative use of PCCs has been reported for treatment of patients with intractable coagulopathic bleeding after cardiac surgery with CPB [
         <a href="#rid44">
          44,46,85,149,150,171-187
         </a>
         ]. Randomized trials and observational studies in cardiac surgical patients have noted reductions in blood transfusions in patients with excessive bleeding and coagulopathy after CPB who received four-factor or three-factor PCC compared with those receiving plasma [
         <a href="#rid85">
          85,177,178,180,181,187
         </a>
         ]. However, prospective data regarding the safety, efficacy, and dosing of PCCs in this setting are limited. Other sources of coagulopathy (eg, surgical sources, thrombocytopenia, hypofibrinogenemia, platelet dysfunction, disseminated intravascular coagulation [DIC]) should be sought and treated. (See
         <a class="medical medical_review" href="/z/d/html/122792.html" rel="external">
          "Achieving hemostasis after cardiac surgery with cardiopulmonary bypass", section on 'Prothrombin complex concentrate products'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Liver transplantation
         </strong>
         – In a propensity score-matched retrospective study of 60 pairs of patients undergoing liver transplantation, PCC use was associated with significantly decreased red blood cell (RBC) and plasma transfusion requirements compared with no PCC use, and no thromboembolic events were noted [
         <a href="#rid188">
          188
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Trauma surgery
         </strong>
         – In trauma patients with findings of trauma-induced coagulopathy, limited data (mostly observational) suggest that administration of four-factor PCC, alone or in combination with
         <a class="drug drug_general" data-topicid="9082" href="/z/d/drug information/9082.html" rel="external">
          fibrinogen concentrate
         </a>
         or plasma, can reduce transfusion of RBCs and other blood components [
         <a href="#rid189">
          189-193
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/117817.html" rel="external">
          "Ongoing assessment, monitoring, and resuscitation of the severely injured patient", section on 'Other agents'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/117817.html" rel="external">
          "Ongoing assessment, monitoring, and resuscitation of the severely injured patient", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – The dose of a PCC product is tailored to the individual patient's needs based on clinical indications and laboratory testing, but typically 1000 to 2000 units is administered. (See
         <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">
          "Management of warfarin-associated bleeding or supratherapeutic INR", section on 'PCC products'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Ideally, point-of-care (POC) viscoelastic testing (VET) such as thromboelastography (TEG) or rotational thromboelastometry (ROTEM) is obtained to monitor overall hemostatic function and supplement information provided by standard laboratory tests (eg, prothrombin time [PT], international normalized ratio [INR], activated partial thromboplastin time [aPTT], fibrinogen level). (See
         <a class="medical medical_review" href="/z/d/html/15147.html" rel="external">
          "Etiology and diagnosis of coagulopathy in trauma patients", section on 'Diagnosis'
         </a>
         and
         <a class="local">
          'Point-of-care tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risks
         </strong>
         – Data for intraoperative safety of PCC are limited [
         <a href="#rid59">
          59,146,171,177,182,187,194
         </a>
         ]. Risk for thromboembolic events may be more likely with repeat or excessive dosing of either four-factor and three-factor PCC, a risk that may extend well into the postoperative period [
         <a href="#rid195">
          195
         </a>
         ]. Also, four factor PCC products contain small amounts of heparin and should not be used in an individual with a known history of heparin-induced thrombocytopenia. (See
         <a class="medical medical_review" href="/z/d/html/7925.html" rel="external">
          "Plasma derivatives and recombinant DNA-produced coagulation factors", section on 'PCCs'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">
          "Management of warfarin-associated bleeding or supratherapeutic INR", section on 'PCC risks'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H931861399">
         <span class="h3">
          Activated PCC
         </span>
         <span class="headingEndMark">
          —
         </span>
         In contrast with standard three- or four-component PCCs, an activated PCC (aPCC; FEIBA) contains activated factor VII  (
         <a class="graphic graphic_table graphicRef94210" href="/z/d/graphic/94210.html" rel="external">
          table 7
         </a>
         ). Due to the greater prothrombotic risk compared with PCC and lack of clinician familiarity, aPCC is not commonly used in the intraoperative setting [
         <a href="#rid171">
          171,194
         </a>
         ]. However, FEIBA may be administered in selected individuals such as those with bleeding due to a factor VIII inhibitor, or bleeding associated with
         <a class="drug drug_general" data-topicid="8691" href="/z/d/drug information/8691.html" rel="external">
          fondaparinux
         </a>
         or
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         when a specific reversal agent is not available. (See
         <a class="medical medical_review" href="/z/d/html/7925.html" rel="external">
          "Plasma derivatives and recombinant DNA-produced coagulation factors", section on 'Recombinant factor VIIa'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94788.html" rel="external">
          "Management of bleeding in patients receiving direct oral anticoagulants", section on 'Dabigatran reversal'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1319.html" rel="external">
          "Fondaparinux: Dosing and adverse effects", section on 'Bleeding/emergency surgery'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3843182136">
         <span class="h2">
          Recombinant activated factor VII (rFVIIa)
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications and uses
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Factor inhibitors
         </strong>
         – Recombinant activated factor VII (rFVIIa) is licensed for prevention of surgical bleeding in patients with hemophilia who have developed an inhibitor to factor VIII or factor IX, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1314.html" rel="external">
          "Treatment of bleeding and perioperative management in hemophilia A and B", section on 'Inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Treatment of life-threatening bleeding in selected surgical procedures
         </strong>
         – In rare instances when intractable bleeding that is potentially life-threatening persists after cardiac or other major surgery, off-label administration of rFVIIa has been reported in attempts to promote clotting and reduce transfusion requirements, after all other efforts have failed [
         <a href="#rid44">
          44,196-199
         </a>
         ]. Similar to off-label use of PCCs, primary causes of coagulopathy should always be sought and treated before considering administration of rFVIIa. Failure to treat the primary coagulation disorder increases the likelihood of inadequate response to the initial dose of rFVIIa [
         <a href="#rid200">
          200-202
         </a>
         ], and may encourage use of higher doses and greater risk of thrombosis [
         <a href="#rid203">
          203,204
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1341.html" rel="external">
          "Recombinant factor VIIa: Administration and adverse effects", section on 'General approach to administration'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Information regarding efficacy of rFVIIa in this setting is largely anecdotal. Systematic reviews have not found a great impact on morbidity and mortality, although transfusion requirements may be reduced [
         <a href="#rid203">
          203,205-207
         </a>
         ]. In cardiac surgical patients, one study reported that a median dose of 13.3 mcg/kg resulted in low overall blood transfusions in cardiac surgical patients [
         <a href="#rid198">
          198
         </a>
         ]. Administration of rFVIIa earlier in the postbypass period when intractable bleeding was identified after transfusion of one or fewer units of RBCs resulted in a relatively lower total dose of rFVIIa (12.2 [9.7-16.4] mcg/kg), whereas higher doses were necessary (18.0 [11.8 to 29.0] mcg/kg) after five or more units of RBCs had been transfused [
         <a href="#rid208">
          208
         </a>
         ]. However, a median of two additional blood components were necessary after administration of rFVIIa regardless of the total dose. (See
         <a class="medical medical_review" href="/z/d/html/1341.html" rel="external">
          "Recombinant factor VIIa: Administration and adverse effects", section on 'Off-label uses'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – Dosing practices vary widely because data are lacking regarding optimal dosing and there are no laboratory tests to monitor drug effect or efficacy. We dose rFVIIa cautiously in small incremental doses of 10 mcg/kg up to a total dose of up to 90 mcg/kg. Stocking the smaller 1 mg vials of rFVIIa facilitates this incremental approach. (See
         <a class="medical medical_review" href="/z/d/html/1341.html" rel="external">
          "Recombinant factor VIIa: Administration and adverse effects", section on 'General approach to administration'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risks
         </strong>
         – High thromboembolism rates &gt;20 percent have been reported in retrospective evaluations of registries for refractory bleeding cases [
         <a href="#rid201">
          201-203
         </a>
         ]. Arterial thromboembolic events have been noted in some trials, particularly in patients with intracranial hemorrhage and those undergoing cardiac surgery [
         <a href="#rid203">
          203,205-207
         </a>
         ]. Thromboembolic complications are more likely with dose escalation, or in the presence of stagnant flow or devices such as extracorporeal membrane oxygenation (ECMO) [
         <a href="#rid44">
          44
         </a>
         ]. Conversely, risk of thrombotic complications may be reduced when lower doses (eg, 10 to 30 mcg/kg) are administered [
         <a href="#rid203">
          203,209
         </a>
         ]. Off-label intraoperative use of rFVIIa is also associated with increased mortality and morbidity (eg, renal failure), especially with administration of higher doses or in older patients [
         <a href="#rid149">
          149,196,203,210,211
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H858314562">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/120167.html" rel="external">
          "Society guideline links: Transfusion and patient blood management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3961591896">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prepare for large surgical blood loss
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Elective surgery
         </strong>
         –
         <strong>
         </strong>
         We obtain preoperative typing and crossmatching and determine whether blood components should be available in the operating room before incision. (See
         <a class="local">
          'Elective surgery with risk for significant blood loss'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Emergency surgery with possible massive transfusion
         </strong>
         –
         <strong>
         </strong>
         Early communication is necessary to activate a massive transfusion protocol. We transfuse red blood cells (RBCs), plasma, and platelets in approximately equal ratios (1:1:1). (See
         <a class="local">
          'Emergency surgery with possibility of massive blood transfusion'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Technical considerations
         </strong>
         – Establish intravenous access. Adhere to protocols for patient identification. Use compatible fluids. Use a blood warmer for cold and previously thawed components. (See
         <a class="local">
          'Technical aspects of blood transfusion'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assess blood loss and bleeding risk
         </strong>
         –
         <strong>
         </strong>
         Blood loss is assessed visually and quantified from blood suction canisters, surgical sponges, and drapes. (See
         <a class="local">
          'Estimating blood loss'
         </a>
         above and
         <a class="local">
          'Intraoperative diagnostic testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Standard tests
         </strong>
         –
         <strong>
         </strong>
         Includes hemoglobin, prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), platelet count, and fibrinogen concentration. (See
         <a class="local">
          'Standard tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Point-of-care (POC) tests
         </strong>
         – POC viscoelastic testing (VET) of coagulation (eg, thromboelastography [TEG], rotational thromboelastometry [ROTEM]) may be used for rapid assessment of causes of coagulopathy and responses to interventions  (
         <a class="graphic graphic_figure graphicRef80241" href="/z/d/graphic/80241.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef100078" href="/z/d/graphic/100078.html" rel="external">
          figure 2
         </a>
         and
         <a class="graphic graphic_table graphicRef74954" href="/z/d/graphic/74954.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef56058" href="/z/d/graphic/56058.html" rel="external">
          table 2
         </a>
         ). POC platelet aggregometry is rarely used. (See
         <a class="local">
          'Tests of coagulation function'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transfusion decisions
         </strong>
         –
         <strong>
         </strong>
         We use protocols or algorithms to guide transfusion decisions  (
         <a class="graphic graphic_table graphicRef53854" href="/z/d/graphic/53854.html" rel="external">
          table 3
         </a>
         ). For patients with significant coagulopathic bleeding, we use VET (if available), rather than standard coagulation tests. Estimates of blood loss, signs of anemia, and intractable microvascular bleeding are also considered. (See
         <a class="local">
          'General principles for transfusion decisions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Restrictive strategy for RBCs
         </strong>
         –
         <strong>
         </strong>
         For most surgical patients without significant ongoing bleeding, we suggest a restrictive strategy, transfusing for hemoglobin &lt;7 g/dL or &lt;8 g/dL rather than higher levels (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The exact restrictive threshold depends on the clinical setting. This includes autologous, salvaged, or allogeneic RBCs. However, decisions are individualized; a hemoglobin threshold of &lt;9 g/dL may be used in selected patients with signs of myocardial or other organ ischemia. (See
         <a class="local">
          'Red blood cells'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Platelets
         </strong>
         –
         <strong>
         </strong>
         We typically maintain a platelet count &gt;50,000/microL (&gt;100,000/microL when ocular central nervous system bleeding is present or likely). Each dose (one apheresis unit or one pool of whole blood-derived platelets) increases the platelet count by 30,000/microL to 50,000/microL (less if platelets are being consumed)  (
         <a class="graphic graphic_table graphicRef53854" href="/z/d/graphic/53854.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Platelets'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Plasma
         </strong>
         –
         <strong>
         </strong>
         Plasma can be used for emergency surgery with severe bleeding and deficiency of multiple coagulation factors, particularly if intracranial hemorrhage is present  (
         <a class="graphic graphic_table graphicRef79151" href="/z/d/graphic/79151.html" rel="external">
          table 4
         </a>
         ). Dosing depends on the degree of deficiency. (See
         <a class="local">
          'Plasma'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cryoprecipitate or
         </strong>
         <strong>
          fibrinogen concentrate
         </strong>
         <strong>
         </strong>
         – We aggressively correct hypofibrinogenemia (&lt;150 mg/dL) if there is active and ongoing bleeding. Cryoprecipitate is more commonly used in the United States and United Kingdom;
         <a class="drug drug_general" data-topicid="9082" href="/z/d/drug information/9082.html" rel="external">
          fibrinogen concentrate
         </a>
         is more often available in continental Europe and Canada. Risks are lower with fibrinogen concentrate  (
         <a class="graphic graphic_table graphicRef102695" href="/z/d/graphic/102695.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="local">
          'Cryoprecipitate or fibrinogen concentrate'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transfusion risks
         </strong>
         – (See
         <a class="local">
          'Risks of blood transfusion'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/95132.html" rel="external">
          "Approach to the patient with a suspected acute transfusion reaction"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clotting factors
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prothrombin complex concentrates (PCCs)
         </strong>
         –
         <strong>
         </strong>
         PCCs are used for emergency treatment of
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         , along with concomitant administration of
         <a class="drug drug_general" data-topicid="9771" href="/z/d/drug information/9771.html" rel="external">
          vitamin K
         </a>
         (
         <a class="graphic graphic_table graphicRef94210" href="/z/d/graphic/94210.html" rel="external">
          table 7
         </a>
         ). PCC or
         <a class="drug drug_general" data-topicid="117811" href="/z/d/drug information/117811.html" rel="external">
          andexanet alfa
         </a>
         can be used for emergency reversal of factor Xa inhibitors. Off-label uses such as intractable coagulopathy and diffuse bleeding after cardiopulmonary bypass (CPB) may be reasonable  (
         <a class="graphic graphic_table graphicRef94210" href="/z/d/graphic/94210.html" rel="external">
          table 7
         </a>
         ). Other causes of intractable microvascular bleeding should be treated before considering a PCC. (See
         <a class="local">
          'Unactivated PCC'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Activated PCC (aPCC; FEIBA) contains activated factor VII and is not commonly used intraoperatively due to greater prothrombotic risk than unactivated PCCs. (See
         <a class="local">
          'Activated PCC'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Recombinant activated factor VII (rFVIIa)
         </strong>
         –
         <strong>
         </strong>
         rFVIIa may be used off-label for intractable life-threatening coagulopathic bleeding after CPB. (See
         <a class="medical medical_review" href="/z/d/html/122792.html" rel="external">
          "Achieving hemostasis after cardiac surgery with cardiopulmonary bypass", section on 'Recombinant activated factor VII'
         </a>
         .)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lou SS, Liu H, Lu C, et al. Personalized Surgical Transfusion Risk Prediction Using Machine Learning to Guide Preoperative Type and Screen Orders. Anesthesiology 2022; 137:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meier JM, Tschoellitsch T. Artificial Intelligence and Machine Learning in Patient Blood Management: A Scoping Review. Anesth Analg 2022; 135:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim K, Satkunasivam R, Nipper C, et al. Association between isolated abnormal coagulation profile on transfusion following major surgery: A NSQIP analysis of individuals without bleeding disorders. Transfusion 2022; 62:2223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shander A, Corwin HL, Meier J, et al. Recommendations From the International Consensus Conference on Anemia Management in Surgical Patients (ICCAMS). Ann Surg 2023; 277:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Philip BK, Philip JH. Characterization of flow in intravenous infusion systems. IEEE Trans Biomed Eng 1983; 30:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McPherson D, Adekanye O, Wilkes AR, Hall JE. Fluid flow through intravenous cannulae in a clinical model. Anesth Analg 2009; 108:1198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jayanthi NV, Dabke HV. The effect of IV cannula length on the rate of infusion. Injury 2006; 37:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barcelona SL, Vilich F, Coté CJ. A comparison of flow rates and warming capabilities of the Level 1 and Rapid Infusion System with various-size intravenous catheters. Anesth Analg 2003; 97:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dutky PA, Stevens SL, Maull KI. Factors affecting rapid fluid resuscitation with large-bore introducer catheters. J Trauma 1989; 29:856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor RW, Palagiri AV. Central venous catheterization. Crit Care Med 2007; 35:1390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanneman MW, Balakrishna A, Lang AL, et al. Improving Transfusion Safety in the Operating Room With a Barcode Scanning System Designed Specifically for the Surgical Environment and Existing Electronic Medical Record Systems: An Interrupted Time Series Analysis. Anesth Analg 2020; 131:1217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nuttall GA, Abenstein JP, Stubbs JR, et al. Computerized bar code-based blood identification systems and near-miss transfusion episodes and transfusion errors. Mayo Clin Proc 2013; 88:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolberg AS, Meng ZH, Monroe DM 3rd, Hoffman M. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma 2004; 56:1221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meng ZH, Wolberg AS, Monroe DM 3rd, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003; 55:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lier H, Krep H, Schroeder S, Stuber F. Preconditions of hemostasis in trauma: a review. The influence of acidosis, hypocalcemia, anemia, and hypothermia on functional hemostasis in trauma. J Trauma 2008; 65:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kermode JC, Zheng Q, Milner EP. Marked temperature dependence of the platelet calcium signal induced by human von Willebrand factor. Blood 1999; 94:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           John M, Ford J, Harper M. Peri-operative warming devices: performance and clinical application. Anaesthesia 2014; 69:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perl T, Bräuer A, Quintel M. Prevention of perioperative hypothermia with forced-air warming systems and upper-body blankets. Surg Technol Int 2006; 15:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madrid E, Urrútia G, Roqué i Figuls M, et al. Active body surface warming systems for preventing complications caused by inadvertent perioperative hypothermia in adults. Cochrane Database Syst Rev 2016; 4:CD009016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sessler DI. Perioperative thermoregulation and heat balance. Lancet 2016; 387:2655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konig G, Yazer MH, Waters JH. Stored platelet functionality is not decreased after warming with a fluid warmer. Anesth Analg 2013; 117:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mattson MK, Groves C, Smith MM, et al. Platelet transfusion: The effects of a fluid warmer on platelet function. Transfusion 2021; 61:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nascimento B, Goodnough LT, Levy JH. Cryoprecipitate therapy. Br J Anaesth 2014; 113:922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shulman AB, Kase YH, Arrigo RT, Hess AS. Coagulated Cryoprecipitate in an Intravenous Line. Anesthesiology 2022; 137:602.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castrillo A, Arroyo JL, Romón Í, et al. Compliance with temperature and time requirements during in-hospital distribution of blood components: A national survey among transfusion services. Transfus Apher Sci 2020; 59:102908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al Kadri HM, Al Anazi BK, Tamim HM. Visual estimation versus gravimetric measurement of postpartum blood loss: a prospective cohort study. Arch Gynecol Obstet 2011; 283:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibon E, Courpied JP, Hamadouche M. Total joint replacement and blood loss: what is the best equation? Int Orthop 2013; 37:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meiser A, Casagranda O, Skipka G, Laubenthal H. [Quantification of blood loss. How precise is visual estimation and what does its accuracy depend on?]. Anaesthesist 2001; 50:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsson C, Saltvedt S, Wiklund I, et al. Estimation of blood loss after cesarean section and vaginal delivery has low validity with a tendency to exaggeration. Acta Obstet Gynecol Scand 2006; 85:1448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kreutziger J, Haim A, Jonsson K, et al. Variation in size of blood puddles on different surfaces. Eur J Emerg Med 2014; 21:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guinn NR, Broomer BW, White W, et al. Comparison of visually estimated blood loss with direct hemoglobin measurement in multilevel spine surgery. Transfusion 2013; 53:2790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lopez-Picado A, Albinarrate A, Barrachina B. Determination of Perioperative Blood Loss: Accuracy or Approximation? Anesth Analg 2017; 125:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gerdessen L, Neef V, Raimann FJ, et al. The visually estimated blood volume in scaled canisters based on a simulation study. BMC Anesthesiol 2021; 21:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broderick AJ. Point-of-care haemoglobin measurement - state of the art or a bleeding nuisance? Anaesthesia 2015; 70:1225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barker SJ, Shander A, Ramsay MA. Continuous Noninvasive Hemoglobin Monitoring: A Measured Response to a Critical Review. Anesth Analg 2016; 122:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kolotiniuk NV, Manecke GR, Pinsky MR, Banks D. Measures of Blood Hemoglobin and Hematocrit During Cardiac Surgery: Comparison of Three Point-of-Care Devices. J Cardiothorac Vasc Anesth 2018; 32:1638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wittenmeier E, Lesmeister L, Pirlich N, et al. Assessment of haemoglobin measurement by several methods - blood gas analyser, capillary and venous HemoCue® , non-invasive spectrophotometry and laboratory assay - in term and preterm infants. Anaesthesia 2019; 74:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegrist KK, Rice MJ. Point-of-Care Blood Testing: The Technology Behind the Numbers. Anesth Analg 2019; 129:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bubenek-Turconi ŞI, Văleanu L, Popescu M, et al. Continuous Noninvasive Hemoglobin Monitoring Reflects the Development of Acute Hemodilution After Consecutive Fluid Challenges. Anesth Analg 2020; 130:696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*. Anesthesiology 2015; 122:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91:944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kozek-Langenecker SA, Ahmed AB, Afshari A, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016. Eur J Anaesthesiol 2017; 34:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curry NS, Davenport R, Pavord S, et al. The use of viscoelastic haemostatic assays in the management of major bleeding: A British Society for Haematology Guideline. Br J Haematol 2018; 182:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raphael J, Mazer CD, Subramani S, et al. Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. Anesth Analg 2019; 129:1209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomas W, Samama CM, Greinacher A, et al. The utility of viscoelastic methods in the prevention and treatment of bleeding and hospital-associated venous thromboembolism in perioperative care: guidance from the SSC of the ISTH. J Thromb Haemost 2018; 16:2336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tibi P, McClure RS, Huang J, et al. STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. Ann Thorac Surg 2021; 112:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wahba A, Milojevic M, Boer C, et al. 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery. Eur J Cardiothorac Surg 2020; 57:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007; 83:S27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA), Boer C, Meesters MI, et al. 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. J Cardiothorac Vasc Anesth 2018; 32:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erdoes G, Koster A, Levy JH. Viscoelastic Coagulation Testing: Use and Current Limitations in Perioperative Decision-making. Anesthesiology 2021; 135:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Görlinger K, Pérez-Ferrer A, Dirkmann D, et al. The role of evidence-based algorithms for rotational thromboelastometry-guided bleeding management. Korean J Anesthesiol 2019; 72:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joshi RV, Wilkey AL, Blackwell JM, et al. Blood Conservation and Hemostasis in Cardiac Surgery: A Survey of Practice Variation and Adoption of Evidence-Based Guidelines. Anesth Analg 2021; 133:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos AS, Oliveira AJF, Barbosa MCL, Nogueira JLDS. Viscoelastic haemostatic assays in the perioperative period of surgical procedures: Systematic review and meta-analysis. J Clin Anesth 2020; 64:109809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wikkelsø A, Wetterslev J, Møller AM, Afshari A. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane Database Syst Rev 2016; :CD007871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serraino GF, Murphy GJ. Routine use of viscoelastic blood tests for diagnosis and treatment of coagulopathic bleeding in cardiac surgery: updated systematic review and meta-analysis. Br J Anaesth 2017; 118:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dias JD, Sauaia A, Achneck HE, et al. Thromboelastography-guided therapy improves patient blood management and certain clinical outcomes in elective cardiac and liver surgery and emergency resuscitation: A systematic review and analysis. J Thromb Haemost 2019; 17:984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wikkelsø A, Wetterslev J, Møller AM, Afshari A. Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to monitor haemostatic treatment in bleeding patients: a systematic review with meta-analysis and trial sequential analysis. Anaesthesia 2017; 72:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deppe AC, Weber C, Zimmermann J, et al. Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: a meta-analysis of 8332 patients. J Surg Res 2016; 203:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber CF, Görlinger K, Meininger D, et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012; 117:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toulon P, Ozier Y, Ankri A, et al. Point-of-care versus central laboratory coagulation testing during haemorrhagic surgery. A multicenter study. Thromb Haemost 2009; 101:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Pietri L, Bianchini M, Montalti R, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology 2016; 63:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avidan MS, Alcock EL, Da Fonseca J, et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth 2004; 92:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson L, Quasim I, Soutar R, et al. An audit of red cell and blood product use after the institution of thromboelastometry in a cardiac intensive care unit. Transfus Med 2006; 16:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spalding GJ, Hartrumpf M, Sierig T, et al. Cost reduction of perioperative coagulation management in cardiac surgery: value of "bedside" thrombelastography (ROTEM). Eur J Cardiothorac Surg 2007; 31:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westbrook AJ, Olsen J, Bailey M, et al. Protocol based on thromboelastograph (TEG) out-performs physician preference using laboratory coagulation tests to guide blood replacement during and after cardiac surgery: a pilot study. Heart Lung Circ 2009; 18:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ak K, Isbir CS, Tetik S, et al. Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: a prospective randomized study. J Card Surg 2009; 24:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Girdauskas E, Kempfert J, Kuntze T, et al. Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial. J Thorac Cardiovasc Surg 2010; 140:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Görlinger K, Dirkmann D, Hanke AA, et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. Anesthesiology 2011; 115:1179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanke AA, Herold U, Dirkmann D, et al. Thromboelastometry Based Early Goal-Directed Coagulation Management Reduces Blood Transfusion Requirements, Adverse Events, and Costs in Acute Type A Aortic Dissection: A Pilot Study. Transfus Med Hemother 2012; 39:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karkouti K, McCluskey SA, Callum J, et al. Evaluation of a novel transfusion algorithm employing point-of-care coagulation assays in cardiac surgery: a retrospective cohort study with interrupted time-series analysis. Anesthesiology 2015; 122:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schaden E, Kimberger O, Kraincuk P, et al. Perioperative treatment algorithm for bleeding burn patients reduces allogeneic blood product requirements. Br J Anaesth 2012; 109:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wong CJ, Vandervoort MK, Vandervoort SL, et al. A cluster-randomized controlled trial of a blood conservation algorithm in patients undergoing total hip joint arthroplasty. Transfusion 2007; 47:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Görlinger K, Fries D, Dirkmann D, et al. Reduction of Fresh Frozen Plasma Requirements by Perioperative Point-of-Care Coagulation Management with Early Calculated Goal-Directed Therapy. Transfus Med Hemother 2012; 39:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meco M, Montisci A, Giustiniano E, et al. Viscoelastic Blood Tests Use in Adult Cardiac Surgery: Meta-Analysis, Meta-Regression, and Trial Sequential Analysis. J Cardiothorac Vasc Anesth 2020; 34:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuiper GJAJM, van Egmond LT, Henskens YMC, et al. Shifts of Transfusion Demand in Cardiac Surgery After Implementation of Rotational Thromboelastometry-Guided Transfusion Protocols: Analysis of the HEROES-CS (HEmostasis Registry of patiEntS in Cardiac Surgery) Observational, Prospective Open Cohort Database. J Cardiothorac Vasc Anesth 2019; 33:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleming K, Redfern RE, March RL, et al. TEG-Directed Transfusion in Complex Cardiac Surgery: Impact on Blood Product Usage. J Extra Corpor Technol 2017; 49:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos AS, Noronha KVMS, Andrade MV. Routine use of viscoelastic blood tests for diagnosis and treatment of coagulopathic bleeding in cardiac surgery. Response to Br J Anaesth 2017; 118: 823-33. Br J Anaesth 2020; 124:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmidt AE, Israel AK, Refaai MA. The Utility of Thromboelastography to Guide Blood Product Transfusion. Am J Clin Pathol 2019; 152:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fahrendorff M, Oliveri RS, Johansson PI. The use of viscoelastic haemostatic assays in goal-directing treatment with allogeneic blood products - A systematic review and meta-analysis. Scand J Trauma Resusc Emerg Med 2017; 25:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franchini M, Mengoli C, Cruciani M, et al. The use of viscoelastic haemostatic assays in non-cardiac surgical settings: a systematic review and meta-analysis. Blood Transfus 2018; 16:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang SC, Shieh JF, Chang KY, et al. Thromboelastography-guided transfusion decreases intraoperative blood transfusion during orthotopic liver transplantation: randomized clinical trial. Transplant Proc 2010; 42:2590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Redfern RE, Fleming K, March RL, et al. Thrombelastography-Directed Transfusion in Cardiac Surgery: Impact on Postoperative Outcomes. Ann Thorac Surg 2019; 107:1313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albert A, Petrov G, Dittberner J, et al. The Impact of Intraoperative Patient Blood Management on Quality Development in Cardiac Surgery. J Cardiothorac Vasc Anesth 2020; 34:2655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karkouti K, Callum J, Wijeysundera DN, et al. Point-of-Care Hemostatic Testing in Cardiac Surgery: A Stepped-Wedge Clustered Randomized Controlled Trial. Circulation 2016; 134:1152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hashmi NK, Ghadimi K, Srinivasan AJ, et al. Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. Vox Sang 2019; 114:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irving AH, Harris A, Petrie D, et al. Impact of patient blood management guidelines on blood transfusions and patient outcomes during cardiac surgery. J Thorac Cardiovasc Surg 2020; 160:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fabbro M 2nd, Winkler AM, Levy JH. Technology: Is There Sufficient Evidence to Change Practice in Point-of-Care Management of Coagulopathy? J Cardiothorac Vasc Anesth 2017; 31:1849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghadimi K, Levy JH, Welsby IJ. Perioperative management of the bleeding patient. Br J Anaesth 2016; 117:iii18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bugaev N, Como JJ, Golani G, et al. Thromboelastography and rotational thromboelastometry in bleeding patients with coagulopathy: Practice management guideline from the Eastern Association for the Surgery of Trauma. J Trauma Acute Care Surg 2020; 89:999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Quellec S, Bordet JC, Negrier C, Dargaud Y. Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature. Thromb Haemost 2016; 116:638.
          </a>
         </li>
         <li class="breakAll">
          Stop the Bleed. American College of Surgeons. Available at: https://www.stopthebleed.org/ (Accessed on August 21, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carson JL, Guyatt G, Heddle NM, et al. Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage. JAMA 2016; 316:2025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: a clinical practice guideline from the AABB*. Ann Intern Med 2012; 157:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy GJ, Pike K, Rogers CA, et al. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med 2015; 372:997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leal-Noval SR, Arellano-Orden V, Muñoz-Gómez M, et al. Red Blood Cell Transfusion Guided by Near Infrared Spectroscopy in Neurocritically Ill Patients with Moderate or Severe Anemia: A Randomized, Controlled Trial. J Neurotrauma 2017; 34:2553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carson JL, Terrin ML, Noveck H, et al. Liberal or restrictive transfusion in high-risk patients after hip surgery. N Engl J Med 2011; 365:2453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bracey AW, Radovancevic R, Riggs SA, et al. Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome. Transfusion 1999; 39:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hajjar LA, Vincent JL, Galas FR, et al. Transfusion requirements after cardiac surgery: The TRACS randomized controlled trial. JAMA 2010; 304:1559.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           So-Osman C, Nelissen R, Te Slaa R, et al. A randomized comparison of transfusion triggers in elective orthopaedic surgery using leucocyte-depleted red blood cells. Vox Sang 2010; 98:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bush RL, Pevec WC, Holcroft JW. A prospective, randomized trial limiting perioperative red blood cell transfusions in vascular patients. Am J Surg 1997; 174:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson RG, Thurer RL, Kruskall MS, et al. Comparison of two transfusion strategies after elective operations for myocardial revascularization. J Thorac Cardiovasc Surg 1992; 104:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brunskill SJ, Millette SL, Shokoohi A, et al. Red blood cell transfusion for people undergoing hip fracture surgery. Cochrane Database Syst Rev 2015; :CD009699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carson JL, Sieber F, Cook DR, et al. Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet 2015; 385:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koch CG, Sessler DI, Mascha EJ, et al. A randomized clinical trial of red blood cell transfusion triggers in cardiac surgery. Ann Thorac Surg 2017; 104:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zerah L, Dourthe L, Cohen-Bittan J, et al. Retrospective Evaluation of a Restrictive Transfusion Strategy in Older Adults with Hip Fracture. J Am Geriatr Soc 2018; 66:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen QH, Wang HL, Liu L, et al. Effects of restrictive red blood cell transfusion on the prognoses of adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. Crit Care 2018; 22:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garg AX, Badner N, Bagshaw SM, et al. Safety of a Restrictive versus Liberal Approach to Red Blood Cell Transfusion on the Outcome of AKI in Patients Undergoing Cardiac Surgery: A Randomized Clinical Trial. J Am Soc Nephrol 2019; 30:1294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shehata N, Mistry N, da Costa BR, et al. Restrictive compared with liberal red cell transfusion strategies in cardiac surgery: a meta-analysis. Eur Heart J 2019; 40:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazer CD, Whitlock RP, Fergusson DA, et al. Restrictive or liberal red-cell transfusion for cardiac surgery. N Engl J Med 2017; 377:2133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazer CD, Whitlock RP, Fergusson DA, et al. Six-Month Outcomes after Restrictive or Liberal Transfusion for Cardiac Surgery. N Engl J Med 2018; 379:1224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chong MA, Krishnan R, Cheng D, Martin J. Should Transfusion Trigger Thresholds Differ for Critical Care Versus Perioperative Patients? A Meta-Analysis of Randomized Trials. Crit Care Med 2018; 46:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hovaguimian F, Myles PS. Restrictive versus Liberal Transfusion Strategy in the Perioperative and Acute Care Settings: A Context-specific Systematic Review and Meta-analysis of Randomized Controlled Trials. Anesthesiology 2016; 125:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trentino KM, Farmer SL, Isbister JP, et al. Restrictive Versus Liberal Transfusion Trials: Are They Asking the Right Question? Anesth Analg 2020; 131:1950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carson JL, Brooks MM, Abbott JD, et al. Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J 2013; 165:964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaikof EL, Brewster DC, Dalman RL, et al. SVS practice guidelines for the care of patients with an abdominal aortic aneurysm: executive summary. J Vasc Surg 2009; 50:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Almeida JP, Vincent JL, Galas FR, et al. Transfusion requirements in surgical oncology patients: a prospective, randomized controlled trial. Anesthesiology 2015; 122:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Will ND, Kor DJ, Frank RD, et al. Initial Postoperative Hemoglobin Values and Clinical Outcomes in Transfused Patients Undergoing Noncardiac Surgery. Anesth Analg 2019; 129:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trentino KM, Leahy MF, Sanfilippo FM, et al. Associations of nadir haemoglobin level and red blood cell transfusion with mortality and length of stay in surgical specialties: a retrospective cohort study. Anaesthesia 2019; 74:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel NN, Murphy GJ. Transfusion triggers in cardiac surgery: Where do we go from here? Can J Anaesth 2018; 65:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dhir A, Tempe DK. Anemia and Patient Blood Management in Cardiac Surgery-Literature Review and Current Evidence. J Cardiothorac Vasc Anesth 2018; 32:2726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elizalde JI, Clemente J, Marín JL, et al. Early changes in hemoglobin and hematocrit levels after packed red cell transfusion in patients with acute anemia. Transfusion 1997; 37:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiesen AR, Hospenthal DR, Byrd JC, et al. Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding. Ann Intern Med 1994; 121:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaPar DJ, Hawkins RB, McMurry TL, et al. Preoperative anemia versus blood transfusion: Which is the culprit for worse outcomes in cardiac surgery? J Thorac Cardiovasc Surg 2018; 156:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuan Y, Zhang Y, Shen L, et al. Perioperative Allogeneic Red Blood Cell Transfusion and Wound Infections: An Observational Study. Anesth Analg 2020; 131:1573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trentino KM, Leahy MF, Erber WN, et al. Hospital-Acquired Infection, Length of Stay, and Readmission in Elective Surgery Patients Transfused 1 Unit of Red Blood Cells: A Retrospective Cohort Study. Anesth Analg 2022; 135:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazzeffi MA, Holmes SD, Taylor B, et al. Red Blood Cell Transfusion and Postoperative Infection in Patients Having Coronary Artery Bypass Grafting Surgery: An Analysis of the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Anesth Analg 2022; 135:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Transfusion of Red Blood Cells, Fresh Frozen Plasma, or Platelets Is Associated With Mortality and Infection After Cardiac Surgery in a Dose-Dependent Manner. Anesth Analg 2020; 130:e32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitlock EL, Kim H, Auerbach AD. Harms associated with single unit perioperative transfusion: retrospective population based analysis. BMJ 2015; 350:h3037.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tantawy H, Li A, Dai F, et al. Association of red blood cell transfusion and short- and longer-term mortality after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2018; 32:1225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rasmussen SR, Kandler K, Nielsen RV, et al. Association between transfusion of blood products and acute kidney injury following cardiac surgery. Acta Anaesthesiol Scand 2020; 64:1397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turan A, Yang D, Bonilla A, et al. Morbidity and mortality after massive transfusion in patients undergoing non-cardiac surgery. Can J Anaesth 2013; 60:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dixon B, Santamaria JD, Reid D, et al. The association of blood transfusion with mortality after cardiac surgery: cause or confounding? (CME). Transfusion 2013; 53:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shander A, Javidroozi M, Naqvi S, et al. An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion (CME). Transfusion 2014; 54:2688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jo KI, Shin JW, Choi TY, et al. Eight-year experience of bloodless surgery at a tertiary care hospital in Korea. Transfusion 2013; 53:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carson JL, Noveck H, Berlin JA, Gould SA. Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion. Transfusion 2002; 42:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hess AS, Ramamoorthy J, Hess JR. Perioperative Platelet Transfusions. Anesthesiology 2021; 134:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baryshnikova E, Di Dedda U, Ranucci M. Are Viscoelastic Tests Clinically Useful to Identify Platelet-Dependent Bleeding in High-Risk Cardiac Surgery Patients? Anesth Analg 2022; 135:1198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warner MA, Chandran A, Frank RD, Kor DJ. Prophylactic Platelet Transfusions for Critically Ill Patients With Thrombocytopenia: A Single-Institution Propensity-Matched Cohort Study. Anesth Analg 2019; 128:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008; 142:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waters JH, Yazer MH. The Mythology of Plasma Transfusion. Anesth Analg 2018; 127:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Callum JL, Karkouti K, Lin Y. Cryoprecipitate: the current state of knowledge. Transfus Med Rev 2009; 23:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen NH, Stensballe J, Afshari A. Comparing efficacy and safety of fibrinogen concentrate to cryoprecipitate in bleeding patients: a systematic review. Acta Anaesthesiol Scand 2016; 60:1033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hensley NB, Mazzeffi MA. Pro-Con Debate: Fibrinogen Concentrate or Cryoprecipitate for Treatment of Acquired Hypofibrinogenemia in Cardiac Surgical Patients. Anesth Analg 2021; 133:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erdoes G, Koster A, Meesters MI, et al. The role of fibrinogen and fibrinogen concentrate in cardiac surgery: an international consensus statement from the Haemostasis and Transfusion Scientific Subcommittee of the European Association of Cardiothoracic Anaesthesiology. Anaesthesia 2019; 74:1589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy JH, Goodnough LT. How I use fibrinogen replacement therapy in acquired bleeding. Blood 2015; 125:1387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Callum J, Farkouh ME, Scales DC, et al. Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial. JAMA 2019; 322:1966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagano D, Milojevic M, Meesters MI, et al. 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. Eur J Cardiothorac Surg 2018; 53:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghadimi K, Welsby IJ. Pro: Factor Concentrates are Essential for Hemostasis in Complex Cardiac Surgery. J Cardiothorac Vasc Anesth 2018; 32:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahe-Meyer N, Solomon C, Hanke A, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. Anesthesiology 2013; 118:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maeda T, Miyata S, Usui A, et al. Safety of Fibrinogen Concentrate and Cryoprecipitate in Cardiovascular Surgery: Multicenter Database Study. J Cardiothorac Vasc Anesth 2019; 33:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li JY, Gong J, Zhu F, et al. Fibrinogen Concentrate in Cardiovascular Surgery: A Meta-analysis of Randomized Controlled Trials. Anesth Analg 2018; 127:612.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wikkelsø A, Lunde J, Johansen M, et al. Fibrinogen concentrate in bleeding patients. Cochrane Database Syst Rev 2013; :CD008864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schöchl H, Nienaber U, Hofer G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010; 14:R55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holcomb JB, Minei KM, Scerbo ML, et al. Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department: experience with 1974 consecutive trauma patients. Ann Surg 2012; 256:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fominskiy E, Nepomniashchikh VA, Lomivorotov VV, et al. Efficacy and Safety of Fibrinogen Concentrate in Surgical Patients: A Meta-Analysis of Randomized Controlled Trials. J Cardiothorac Vasc Anesth 2016; 30:1196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neerman-Arbez M, Casini A. Clinical Consequences and Molecular Bases of Low Fibrinogen Levels. Int J Mol Sci 2018; 19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrison GA, Koch J, Royds M, et al. Fibrinogen concentrate vs. fresh frozen plasma for the management of coagulopathy during thoraco-abdominal aortic aneurysm surgery: a pilot randomised controlled trial. Anaesthesia 2019; 74:180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen W, Shen J, Zhang Y, et al. A randomised controlled trial of fibrinogen concentrate during scoliosis surgery. Anaesthesia 2020; 75:1476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion 2014; 54:1389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sørensen B, Bevan D. A critical evaluation of cryoprecipitate for replacement of fibrinogen. Br J Haematol 2010; 149:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng KT, Yap JLL, Kwok PE. The effect of fibrinogen concentrate on postoperative blood loss: A systematic review and meta-analysis of randomized controlled trials. J Clin Anesth 2020; 63:109782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilecen S, de Groot JA, Kalkman CJ, et al. Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery: A Randomized Clinical Trial. JAMA 2017; 317:738.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahe-Meyer N, Levy JH, Mazer CD, et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy. Br J Anaesth 2016; 117:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ranucci M, Di Dedda U, Baryshnikova E. Trials and Tribulations of Viscoelastic-Based Determination of Fibrinogen Concentration. Anesth Analg 2020; 130:644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McVey MJ, Kapur R, Cserti-Gazdewich C, et al. Transfusion-related Acute Lung Injury in the Perioperative Patient. Anesthesiology 2019; 131:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clebone A. Transfusion reactions and cognitive aids. Curr Opin Anaesthesiol 2019; 32:242.
          </a>
         </li>
         <li class="breakAll">
          http://emergencymanual.stanford.edu/ (Accessed on December 16, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy JH, Douketis J, Steiner T, et al. Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Non-vitamin K Anticoagulant Reversal. Anesthesiology 2018; 129:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghadimi K, Levy JH, Welsby IJ. Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting. Anesth Analg 2016; 122:1287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MM, Ashikhmina E, Brinkman NJ, Barbara DW. Perioperative Use of Coagulation Factor Concentrates in Patients Undergoing Cardiac Surgery. J Cardiothorac Vasc Anesth 2017; 31:1810.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldhammer JE, Herman CR. A Split From Conventional Blood Component Therapy? J Cardiothorac Vasc Anesth 2018; 32:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun GH, Patel V, Moreno-Duarte I, et al. Intraoperative Administration of 4-Factor Prothrombin Complex Concentrate Reduces Blood Requirements in Cardiac Transplantation. J Cardiothorac Vasc Anesth 2018; 32:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatt HV, Subramaniam K. PRO: Prothrombin Complex Concentrate Should Be Used in Preference to Fresh Frozen Plasma for Hemostasis in Cardiac Surgical Patients. J Cardiothorac Vasc Anesth 2018; 32:1062.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grottke O, Schulman S. Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors. Anesthesiology 2019; 131:1153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith MM, Schroeder DR, Nelson JA, et al. Prothrombin Complex Concentrate vs Plasma for Post-Cardiopulmonary Bypass Coagulopathy and Bleeding: A Randomized Clinical Trial. JAMA Surg 2022; 157:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karkouti K, Bartoszko J, Grewal D, et al. Comparison of 4-Factor Prothrombin Complex Concentrate With Frozen Plasma for Management of Hemorrhage During and After Cardiac Surgery: A Randomized Pilot Trial. JAMA Netw Open 2021; 4:e213936.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erdoes G, Koster A, Ortmann E, et al. A European consensus statement on the use of four-factor prothrombin complex concentrate for cardiac and non-cardiac surgical patients. Anaesthesia 2021; 76:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nemeth E, Varga T, Soltesz A, et al. Perioperative Factor Concentrate Use is Associated With More Beneficial Outcomes and Reduced Complication Rates Compared With a Pure Blood Product-Based Strategy in Patients Undergoing Elective Cardiac Surgery: A Propensity Score-Matched Cohort Study. J Cardiothorac Vasc Anesth 2022; 36:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayes K, Fernando MC, Jordan V. Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding. Cochrane Database Syst Rev 2022; 11:CD013551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fries D. The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding. Transfusion 2013; 53 Suppl 1:91S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitzgerald J, Lenihan M, Callum J, et al. Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma. Br J Anaesth 2018; 120:928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cappabianca G, Mariscalco G, Biancari F, et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Crit Care 2016; 20:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ortmann E, Besser MW, Sharples LD, et al. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. Anesth Analg 2015; 121:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnékian V, Camous J, Fattal S, et al. Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interact Cardiovasc Thorac Surg 2012; 15:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roman M, Biancari F, Ahmed AB, et al. Prothrombin Complex Concentrate in Cardiac Surgery: A Systematic Review and Meta-Analysis. Ann Thorac Surg 2019; 107:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srivastava P, Agarwal A, Jha A, et al. Utility of prothrombin complex concentrate as first-line treatment modality of coagulopathy in patients undergoing liver transplantation: A propensity score-matched study. Clin Transplant 2018; 32:e13435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jehan F, Aziz H, OʼKeeffe T, et al. The role of four-factor prothrombin complex concentrate in coagulopathy of trauma: A propensity matched analysis. J Trauma Acute Care Surg 2018; 85:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schöchl H, Nienaber U, Maegele M, et al. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care 2011; 15:R83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Innerhofer P, Westermann I, Tauber H, et al. The exclusive use of coagulation factor concentrates enables reversal of coagulopathy and decreases transfusion rates in patients with major blunt trauma. Injury 2013; 44:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Innerhofer P, Fries D, Mittermayr M, et al. Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. Lancet Haematol 2017; 4:e258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeeshan M, Hamidi M, Kulvatunyou N, et al. 3-Factor Versus 4-Factor PCC in Coagulopathy of Trauma: Four is Better Than Three. Shock 2019; 52:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song HK, Tibayan FA, Kahl EA, et al. Safety and efficacy of prothrombin complex concentrates for the treatment of coagulopathy after cardiac surgery. J Thorac Cardiovasc Surg 2014; 147:1036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus 2010; 8:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodnough LT, Levy JH. The Judicious Use of Recombinant Factor VIIa. Semin Thromb Hemost 2016; 42:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peralta MR, Chowdary P. The use of new procoagulants in blunt and penetrating trauma. Curr Opin Anaesthesiol 2019; 32:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baral P, Cotter E, Gao G, et al. Characteristics Associated With Mortality in 372 Patients Receiving Low-Dose Recombinant Factor VIIa (rFVIIa) for Cardiac Surgical Bleeding. J Cardiothorac Vasc Anesth 2019; 33:2133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hessel EA 2nd. What's New in Cardiopulmonary Bypass. J Cardiothorac Vasc Anesth 2019; 33:2296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen ND, Bhattacharya SD, Williams JB, et al. Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations. Ann Thorac Surg 2012; 93:1921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karkouti K, Beattie WS, Arellano R, et al. Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. Circulation 2008; 118:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AI, Campigotto F, Rawn JD, et al. Clinical significance of coagulation studies in predicting response to activated recombinant Factor VII in cardiac surgery patients. Br J Haematol 2012; 157:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med 2010; 363:1791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill R, Herbertson M, Vuylsteke A, et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009; 120:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yank V, Tuohy CV, Logan AC, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 2011; 154:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin Y, Stanworth S, Birchall J, et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2011; :CD005011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simpson E, Lin Y, Stanworth S, et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2012; :CD005011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sutherland L, Houchin A, Wang T, et al. Impact of Early, Low-Dose Factor VIIa on Subsequent Transfusions and Length of Stay in Cardiac Surgery. J Cardiothorac Vasc Anesth 2022; 36:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brase J, Finger B, He J, et al. Analysis of Outcomes Using Low-Dose and Early Administration of Recombinant Activated Factor VII in Cardiac Surgery. Ann Thorac Surg 2016; 102:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alfirevic A, Duncan A, You J, et al. Recombinant factor VII is associated with worse survival in complex cardiac surgical patients. Ann Thorac Surg 2014; 98:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harper PC, Smith MM, Brinkman NJ, et al. Outcomes Following Three-Factor Inactive Prothrombin Complex Concentrate Versus Recombinant Activated Factor VII Administration During Cardiac Surgery. J Cardiothorac Vasc Anesth 2018; 32:151.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 112610 Version 24.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35147666" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Personalized Surgical Transfusion Risk Prediction Using Machine Learning to Guide Preoperative Type and Screen Orders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35977362" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Artificial Intelligence and Machine Learning in Patient Blood Management: A Scoping Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36250486" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Association between isolated abnormal coagulation profile on transfusion following major surgery: A NSQIP analysis of individuals without bleeding disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36134567" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Recommendations From the International Consensus Conference on Anemia Management in Surgical Patients (ICCAMS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6662525" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Characterization of flow in intravenous infusion systems.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19299786" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Fluid flow through intravenous cannulae in a clinical model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16356500" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The effect of IV cannula length on the rate of infusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12873917" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A comparison of flow rates and warming capabilities of the Level 1 and Rapid Infusion System with various-size intravenous catheters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2738983" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Factors affecting rapid fluid resuscitation with large-bore introducer catheters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17414086" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Central venous catheterization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32925343" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Improving Transfusion Safety in the Operating Room With a Barcode Scanning System Designed Specifically for the Surgical Environment and Existing Electronic Medical Record Systems: An Interrupted Time Series Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23541010" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Computerized bar code-based blood identification systems and near-miss transfusion episodes and transfusion errors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15211129" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14608161" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18849817" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Preconditions of hemostasis in trauma: a review. The influence of acidosis, hypocalcemia, anemia, and hypothermia on functional hemostasis in trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10381514" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Marked temperature dependence of the platelet calcium signal induced by human von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24720346" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Peri-operative warming devices: performance and clinical application.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17029156" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Prevention of perioperative hypothermia with forced-air warming systems and upper-body blankets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27098439" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Active body surface warming systems for preventing complications caused by inadvertent perioperative hypothermia in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26775126" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Perioperative thermoregulation and heat balance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23921655" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Stored platelet functionality is not decreased after warming with a fluid warmer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33078463" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Platelet transfusion: The effects of a fluid warmer on platelet function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24972790" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Cryoprecipitate therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35881767" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Coagulated Cryoprecipitate in an Intravenous Line.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32921561" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Compliance with temperature and time requirements during in-hospital distribution of blood components: A national survey among transfusion services.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20508942" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Visual estimation versus gravimetric measurement of postpartum blood loss: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23385607" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Total joint replacement and blood loss: what is the best equation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11220251" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : [Quantification of blood loss. How precise is visual estimation and what does its accuracy depend on?].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17260220" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Estimation of blood loss after cesarean section and vaginal delivery has low validity with a tendency to exaggeration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24217851" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Variation in size of blood puddles on different surfaces.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23438094" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Comparison of visually estimated blood loss with direct hemoglobin measurement in multilevel spine surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28368940" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Determination of Perioperative Blood Loss: Accuracy or Approximation?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33593299" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The visually estimated blood volume in scaled canisters based on a simulation study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26374281" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Point-of-care haemoglobin measurement - state of the art or a bleeding nuisance?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25746056" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Continuous Noninvasive Hemoglobin Monitoring: A Measured Response to a Critical Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29276094" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Measures of Blood Hemoglobin and Hematocrit During Cardiac Surgery: Comparison of Three Point-of-Care Devices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30427065" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Assessment of haemoglobin measurement by several methods - blood gas analyser, capillary and venous HemoCue®, non-invasive spectrophotometry and laboratory assay - in term and preterm infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30973383" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Point-of-Care Blood Testing: The Technology Behind the Numbers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31306244" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Continuous Noninvasive Hemoglobin Monitoring Reflects the Development of Acute Hemodilution After Consecutive Fluid Challenges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25545654" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21353044" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28459785" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: First update 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30073664" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The use of viscoelastic haemostatic assays in the management of major bleeding: A British Society for Haematology Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31613811" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30171663" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The utility of viscoelastic methods in the prevention and treatment of bleeding and hospital-associated venous thromboembolism in perioperative care: guidance from the SSC of the ISTH.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34217505" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31576396" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17462454" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29029990" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33979438" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Viscoelastic Coagulation Testing: Use and Current Limitations in Perioperative Decision-making.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31096732" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The role of evidence-based algorithms for rotational thromboelastometry-guided bleeding management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33939648" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Blood Conservation and Hemostasis in Cardiac Surgery: A Survey of Practice Variation and Adoption of Evidence-Based Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32299044" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Viscoelastic haemostatic assays in the perioperative period of surgical procedures: Systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27552162" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28475665" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Routine use of viscoelastic blood tests for diagnosis and treatment of coagulopathic bleeding in cardiac surgery: updated systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30947389" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Thromboelastography-guided therapy improves patient blood management and certain clinical outcomes in elective cardiac and liver surgery and emergency resuscitation: A systematic review and analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28052313" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to monitor haemostatic treatment in bleeding patients: a systematic review with meta-analysis and trial sequential analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27363652" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: a meta-analysis of 8332 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22914710" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19190827" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Point-of-care versus central laboratory coagulation testing during haemorrhagic surgery. A multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26340411" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14722166" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16480437" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : An audit of red cell and blood product use after the institution of thromboelastometry in a cardiac intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17398108" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Cost reduction of perioperative coagulation management in cardiac surgery: value of "bedside" thrombelastography (ROTEM).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19117801" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Protocol based on thromboelastograph (TEG) out-performs physician preference using laboratory coagulation tests to guide blood replacement during and after cardiac surgery: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19583608" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Thromboelastography-based transfusion algorithm reduces blood product use after elective CABG: a prospective randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20951260" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21970887" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22670130" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Thromboelastometry Based Early Goal-Directed Coagulation Management Reduces Blood Transfusion Requirements, Adverse Events, and Costs in Acute Type A Aortic Dissection: A Pilot Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25485470" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Evaluation of a novel transfusion algorithm employing point-of-care coagulation assays in cardiac surgery: a retrospective cohort study with interrupted time-series analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22719014" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Perioperative treatment algorithm for bleeding burn patients reduces allogeneic blood product requirements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17465948" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : A cluster-randomized controlled trial of a blood conservation algorithm in patients undergoing total hip joint arthroplasty.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22670128" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Reduction of Fresh Frozen Plasma Requirements by Perioperative Point-of-Care Coagulation Management with Early Calculated Goal-Directed Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31445833" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Viscoelastic Blood Tests Use in Adult Cardiac Surgery: Meta-Analysis, Meta-Regression, and Trial Sequential Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30269889" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Shifts of Transfusion Demand in Cardiac Surgery After Implementation of Rotational Thromboelastometry-Guided Transfusion Protocols: Analysis of the HEROES-CS (HEmostasis Registry of patiEntS in Cardiac Surgery) Observational, Prospective Open Cohort Database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29302119" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : TEG-Directed Transfusion in Complex Cardiac Surgery: Impact on Blood Product Usage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31653395" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Routine use of viscoelastic blood tests for diagnosis and treatment of coagulopathic bleeding in cardiac surgery. Response to Br J Anaesth 2017; 118: 823-33.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31263903" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : The Utility of Thromboelastography to Guide Blood Product Transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28403868" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The use of viscoelastic haemostatic assays in goal-directing treatment with allogeneic blood products - A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29517967" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : The use of viscoelastic haemostatic assays in non-cardiac surgical settings: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20832550" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Thromboelastography-guided transfusion decreases intraoperative blood transfusion during orthotopic liver transplantation: randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30768933" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Thrombelastography-Directed Transfusion in Cardiac Surgery: Impact on Postoperative Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32546407" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The Impact of Intraoperative Patient Blood Management on Quality Development in Cardiac Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27654344" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Point-of-Care Hemostatic Testing in Cardiac Surgery: A Stepped-Wedge Clustered Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30937927" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31711621" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Impact of patient blood management guidelines on blood transfusions and patient outcomes during cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28844370" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Technology: Is There Sufficient Evidence to Change Practice in Point-of-Care Management of Coagulopathy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27940453" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Perioperative management of the bleeding patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32941349" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Thromboelastography and rotational thromboelastometry in bleeding patients with coagulopathy: Practice management guideline from the Eastern Association for the Surgery of Trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27440202" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27440202" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Comparison of current platelet functional tests for the assessment of aspirin and clopidogrel response. A review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27732721" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22751760" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Red blood cell transfusion: a clinical practice guideline from the AABB*.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25760354" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Liberal or restrictive transfusion after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28486023" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Red Blood Cell Transfusion Guided by Near Infrared Spectroscopy in Neurocritically Ill Patients with Moderate or Severe Anemia: A Randomized, Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22168590" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Liberal or restrictive transfusion in high-risk patients after hip surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10532600" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Lowering the hemoglobin threshold for transfusion in coronary artery bypass procedures: effect on patient outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20940381" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Transfusion requirements after cardiac surgery: The TRACS randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19656349" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : A randomized comparison of transfusion triggers in elective orthopaedic surgery using leucocyte-depleted red blood cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9293831" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : A prospective, randomized trial limiting perioperative red blood cell transfusions in vascular patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1495291" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Comparison of two transfusion strategies after elective operations for myocardial revascularization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25897628" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Red blood cell transfusion for people undergoing hip fracture surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25499165" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28821336" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : A randomized clinical trial of red blood cell transfusion triggers in cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29676780" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Retrospective Evaluation of a Restrictive Transfusion Strategy in Older Adults with Hip Fracture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29848364" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Effects of restrictive red blood cell transfusion on the prognoses of adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31221679" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Safety of a Restrictive versus Liberal Approach to Red Blood Cell Transfusion on the Outcome of AKI in Patients Undergoing Cardiac Surgery: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30107514" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Restrictive compared with liberal red cell transfusion strategies in cardiac surgery: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29130845" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Restrictive or liberal red-cell transfusion for cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30146969" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Six-Month Outcomes after Restrictive or Liberal Transfusion for Cardiac Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29189348" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Should Transfusion Trigger Thresholds Differ for Critical Care Versus Perioperative Patients? A Meta-Analysis of Randomized Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27167445" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Restrictive versus Liberal Transfusion Strategy in the Perioperative and Acute Care Settings: A Context-specific Systematic Review and Meta-analysis of Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33044262" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Restrictive Versus Liberal Transfusion Trials: Are They Asking the Right Question?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23708168" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19786241" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : SVS practice guidelines for the care of patients with an abdominal aortic aneurysm: executive summary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25401417" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Transfusion requirements in surgical oncology patients: a prospective, randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31425225" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Initial Postoperative Hemoglobin Values and Clinical Outcomes in Transfused Patients Undergoing Noncardiac Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30933308" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Associations of nadir haemoglobin level and red blood cell transfusion with mortality and length of stay in surgical specialties: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29785675" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Transfusion triggers in cardiac surgery: Where do we go from here?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29307702" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Anemia and Patient Blood Management in Cardiac Surgery-Literature Review and Current Evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9191816" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Early changes in hemoglobin and hematocrit levels after packed red cell transfusion in patients with acute anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8037410" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29706372" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Preoperative anemia versus blood transfusion: Which is the culprit for worse outcomes in cardiac surgery?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33079881" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Perioperative Allogeneic Red Blood Cell Transfusion and Wound Infections: An Observational Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35977367" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Hospital-Acquired Infection, Length of Stay, and Readmission in Elective Surgery Patients Transfused 1 Unit of Red Blood Cells: A Retrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35977365" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Red Blood Cell Transfusion and Postoperative Infection in Patients Having Coronary Artery Bypass Grafting Surgery: An Analysis of the Society of Thoracic Surgeons Adult Cardiac Surgery Database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31702696" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Transfusion of Red Blood Cells, Fresh Frozen Plasma, or Platelets Is Associated With Mortality and Infection After Cardiac Surgery in a Dose-Dependent Manner.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26070979" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Harms associated with single unit perioperative transfusion: retrospective population based analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29402623" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Association of red blood cell transfusion and short- and longer-term mortality after coronary artery bypass graft surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32609377" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Association between transfusion of blood products and acute kidney injury following cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23609882" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Morbidity and mortality after massive transfusion in patients undergoing non-cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22574710" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : The association of blood transfusion with mortality after cardiac surgery: cause or confounding? (CME).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24527739" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : An update on mortality and morbidity in patients with very low postoperative hemoglobin levels who decline blood transfusion (CME).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22924834" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Eight-year experience of bloodless surgery at a tertiary care hospital in Korea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12375651" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Mortality and morbidity in patients with very low postoperative Hb levels who decline blood transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33411916" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Perioperative Platelet Transfusions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36227767" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Are Viscoelastic Tests Clinically Useful to Identify Platelet-Dependent Bleeding in High-Risk Cardiac Surgery Patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29293185" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Prophylactic Platelet Transfusions for Critically Ill Patients With Thrombocytopenia: A Single-Institution Propensity-Matched Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18510692" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Platelet transfusion refractoriness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30028386" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : The Mythology of Plasma Transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15198728" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19539873" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Cryoprecipitate: the current state of knowledge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27109179" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Comparing efficacy and safety of fibrinogen concentrate to cryoprecipitate in bleeding patients: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34127586" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Pro-Con Debate: Fibrinogen Concentrate or Cryoprecipitate for Treatment of Acquired Hypofibrinogenemia in Cardiac Surgical Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31531856" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : The role of fibrinogen and fibrinogen concentrate in cardiac surgery: an international consensus statement from the Haemostasis and Transfusion Scientific Subcommittee of the European Association of Cardiothoracic Anaesthesiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23656742" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25519751" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : How I use fibrinogen replacement therapy in acquired bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31634905" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29029100" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29217233" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Pro: Factor Concentrates are Essential for Hemostasis in Complex Cardiac Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23249928" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30057251" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Safety of Fibrinogen Concentrate and Cryoprecipitate in Cardiovascular Surgery: Multicenter Database Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29863608" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Fibrinogen Concentrate in Cardiovascular Surgery: A Meta-analysis of Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23986527" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Fibrinogen concentrate in bleeding patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20374650" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22868371" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department: experience with 1974 consecutive trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27493092" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Efficacy and Safety of Fibrinogen Concentrate in Surgical Patients: A Meta-Analysis of Randomized Controlled Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29316703" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Clinical Consequences and Molecular Bases of Low Fibrinogen Levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30467829" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Fibrinogen concentrate vs. fresh frozen plasma for the management of coagulopathy during thoraco-abdominal aortic aneurysm surgery: a pilot randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32500569" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : A randomised controlled trial of fibrinogen concentrate during scoliosis surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24117955" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20456356" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : A critical evaluation of cryoprecipitate for replacement of fibrinogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32193125" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : The effect of fibrinogen concentrate on postoperative blood loss: A systematic review and meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28241354" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Effect of Fibrinogen Concentrate on Intraoperative Blood Loss Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27317703" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31725023" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Trials and Tribulations of Viscoelastic-Based Determination of Fibrinogen Concentration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31408449" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Transfusion-related Acute Lung Injury in the Perioperative Patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30817401" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Transfusion reactions and cognitive aids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30817401" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Transfusion reactions and cognitive aids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30157037" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Non-vitamin K Anticoagulant Reversal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26983050" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28838728" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Perioperative Use of Coagulation Factor Concentrates in Patients Undergoing Cardiac Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29126681" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : A Split From Conventional Blood Component Therapy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29198634" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Intraoperative Administration of 4-Factor Prothrombin Complex Concentrate Reduces Blood Requirements in Cardiac Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29336960" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : PRO: Prothrombin Complex Concentrate Should Be Used in Preference to Fresh Frozen Plasma for Hemostasis in Cardiac Surgical Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31415251" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Four-factor Prothrombin Complex Concentrate for the Management of Patients Receiving Direct Oral Activated Factor X Inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35767271" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Prothrombin Complex Concentrate vs Plasma for Post-Cardiopulmonary Bypass Coagulopathy and Bleeding: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33792729" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Comparison of 4-Factor Prothrombin Complex Concentrate With Frozen Plasma for Management of Hemorrhage During and After Cardiac Surgery: A Randomized Pilot Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32681570" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : A European consensus statement on the use of four-factor prothrombin complex concentrate for cardiac and non-cardiac surgical patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33941446" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Perioperative Factor Concentrate Use is Associated With More Beneficial Outcomes and Reduced Complication Rates Compared With a Pure Blood Product-Based Strategy in Patients Undergoing Elective Cardiac Surgery: A Propensity Score-Matched Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36408876" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23301979" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : The early use of fibrinogen, prothrombin complex concentrate, and recombinant-activated factor VIIa in massive bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29661410" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Use of prothrombin complex concentrate for management of coagulopathy after cardiac surgery: a propensity score matched comparison to plasma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26738468" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25822921" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22623627" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30458156" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : Prothrombin Complex Concentrate in Cardiac Surgery: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30375084" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Utility of prothrombin complex concentrate as first-line treatment modality of coagulopathy in patients undergoing liver transplantation: A propensity score-matched study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29664892" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : The role of four-factor prothrombin complex concentrate in coagulopathy of trauma: A propensity matched analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21375741" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23000050" id="rid190" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          191 : The exclusive use of coagulation factor concentrates enables reversal of coagulopathy and decreases transfusion rates in patients with major blunt trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28457980" id="rid191" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          192 : Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30074978" id="rid192" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          193 : 3-Factor Versus 4-Factor PCC in Coagulopathy of Trauma: Four is Better Than Three.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24365268" id="rid193" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          194 : Safety and efficacy of prothrombin complex concentrates for the treatment of coagulopathy after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20671873" id="rid194" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          195 : Prothrombin complex concentrates: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26838698" id="rid195" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          196 : The Judicious Use of Recombinant Factor VIIa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30817396" id="rid196" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          197 : The use of new procoagulants in blunt and penetrating trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30772178" id="rid197" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          198 : Characteristics Associated With Mortality in 372 Patients Receiving Low-Dose Recombinant Factor VIIa (rFVIIa) for Cardiac Surgical Bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30928282" id="rid198" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          199 : What's New in Cardiopulmonary Bypass.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22551846" id="rid199" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          200 : Intraoperative use of low-dose recombinant activated factor VII during thoracic aortic operations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18606914" id="rid200" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          201 : Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22224596" id="rid201" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          202 : Clinical significance of coagulation studies in predicting response to activated recombinant Factor VII in cardiac surgery patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21047223" id="rid202" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          203 : Safety of recombinant activated factor VII in randomized clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19546387" id="rid203" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          204 : Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21502651" id="rid204" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          205 : Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21328270" id="rid205" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          206 : Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22419303" id="rid206" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          207 : Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34103218" id="rid207" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          208 : Impact of Early, Low-Dose Factor VIIa on Subsequent Transfusions and Length of Stay in Cardiac Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26874365" id="rid208" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          209 : Analysis of Outcomes Using Low-Dose and Early Administration of Recombinant Activated Factor VII in Cardiac Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24968771" id="rid209" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          210 : Recombinant factor VII is associated with worse survival in complex cardiac surgical patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29217234" id="rid210" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          211 : Outcomes Following Three-Factor Inactive Prothrombin Complex Concentrate Versus Recombinant Activated Factor VII Administration During Cardiac Surgery.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
